Improved methods and compositions for the treatment of blistering skin diseases

Small compound agonists targeting Mas and/or MrgD receptors effectively treat blistering skin diseases by reducing blister formation and improving skin integrity, addressing the limitations of current therapies for autoimmune and non-autoimmune conditions.

WO2026241453A1PCT designated stage Publication Date: 2026-11-19CONSTANT THERAPEUTICS LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028079
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-14
Filing Date
2026-05-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current therapies for blistering skin diseases, such as pemphigus and pemphigoid, are inadequate, particularly in terms of curative treatments, and prolonged systemic immunosuppression poses challenges, while nonimmunobullous diseases like epidermolysis bullosa lack effective drug treatments.

Method used

Administration of small compound agonists targeting the Mas and/or MrgD receptors, specifically compounds of Formula (A) or (B), to treat autoimmune and non-autoimmune blistering skin diseases, including pemphigus, pemphigoid, and epidermolysis bullosa, by ameliorating the damage or disruption between skin layers.

Benefits of technology

The small compound agonists significantly reduce blister formation and improve skin integrity, providing therapeutic benefits for various blistering skin diseases, including a reduction in affected skin area and amelioration of symptoms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000017_0001
    Figure IMGF000017_0001
Patent Text Reader

Abstract

The present invention provides, among other things, improved methods and compositions for treating skin blistering diseases comprising administering to a subject suffering from pemphigus or pemphigoid a small compound, wherein the administration results in a reduction in the intensity, severity, duration, or frequency of at least one symptom of a skin blistering disease.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Attorney Docket No.: 778138: CST9-008PC

[0002] IMPROVED METHODS AND COMPOSITIONS FOR THE TREATMENT

[0003] OF BLISTERING SKIN DISEASES

[0004] CROSS REFERENCE TO RELATED APPLICATION

[0005] This application claims the benefit of U. S. Provisional Patent Application Serial No. 63 / 805,546, filed May 14, 2025. The entire content of the above-referenced patent application is incorporated by reference in its entirety herein.

[0006] BACKGROUND

[0007] Blistering skin diseases are conditions in which the skin forms vesicles or bullae. There are two main groups of blistering skin diseases, immunobullous and nonimmunobullous skin diseases, which have in common that they are due to damage or disruption between skin layers. Therefore, they are in principle all treatable by agents ameliorating or even improving this kind of damage or disruption.

[0008] Immunobullous diseases are autoimmune blistering skin diseases including Pemphigus and pemphigoid disease. These are autoimmune blistering skin diseases or disorders characterized by the formation of blisters in the skin or membranes of mouth, nose or eyes, for example, due to autoantibodies that attack normal body structures. Pemphigus is characterized by shallow ulcers in the epidermis causing fragile blisters that break quickly, while pemphigoid causes deeper, tense blisters in the layer between epidermis and dermis that are not easily disrupted. They are also associated with hives. Current therapy includes, for example, corticosteroid treatment, mycophenolate mofetil and rituximab. Pemphigus and pemphigoid disease may cause fatalities. Prolonged systemic immunosuppression remains challenging.

[0009] Nonimmunobullous diseases include, e.g., genetic disorders such as epidermolysis bullosa (EB), which is a genetic skin disease that is inherited in an autosomal dominant or recessive manner. The cause is a congenital mutation in certain genes, whose gene products are necessary, among other things, for the intact cellular structure of the skin. The mechanical connection between the different skin layers is insufficiently developed. Depending on the subtype, this can lead to blisters and wounds with possible scarring (on and throughout the body, for example, also in the mouth (microstomia) and esophagus). EB leads to more or less severe disabilitiesAttorney Docket No.: 778138: CST9-008PC and can cause premature death. Possible impairments and consequences include malnutrition, short stature, finger and toe adhesions, tooth decay, hair loss, impaired mobility, skin cancer, and pain. Treatment involves multiple daily wound care. There is currently no curative therapy. A topical gene therapy was approved by the FDA in 2023 (Vyjuvek®), but no drug treatment is currently available.

[0010] The inventors found that agonists of Mas and / or MrgD receptor are useful in the treatment of blistering skin diseases and the present invention provides small compound agonists accordingly.

[0011] SUMMARY OF THE INVENTION

[0012] The invention relates to a method of treating a blistering skin disease comprising administering a small compound to a subject suffering from the blistering skin disease. The invention also relates to a small compound for use in treating a blistering skin disease. Also, the invention relates to the use of small compound in the manufacture of a medicament for treating an autoimmune blistering skin disease.

[0013] The small compound used in the present invention is a compound having the structure according to Formula (A):

[0014]

[0015] or a pharmaceutically acceptable salt thereof, wherein

[0016] each of R1and R5is independently H or Ci-Ce alkyl;

[0017] R2is independently H, OH, or (CH2)PCO2R5;

[0018] R3is independently Ci-Ce alkyl, 1- to 6-membered heteroalkyl, or X1-R6;

[0019] R4is independently Ci-Ce alkyl, 1- to 6-membered heteroalkyl, or X’-R6, or two R4on adjacent carbons combine to form a heteroaryl moiety, or one R4combines with R7Bto form a heteroaryl moiety;

[0020] L1is independently a covalent bond, C(O), C(O)NR7A, or NR7AC(O);

[0021] L2is independently a covalent bond, CH2, C(O), NR7B, C(O)NR7B, or NR7BC(O);

[0022] R6is independently Ce-Cio aryl or 5- to 10-membered heteroaryl;

[0023] each R7Ais independently H or Ci-Ce alkyl;

[0024] Attorney Docket No.: 778138: CST9-008PC each R7Bis independently H or Ci-Ce alkyl, or R7Bcombines with R4to form a heteroaryl moiety;

[0025] X1is independently a covalent bond, O, or CH2;

[0026] Cy is independently C5-C10 cycloalkyl, 5- to 7-membered heterocyclyl, 5- to 6-membered heteroaryl or phenyl;

[0027] each of m, n, and o is independently 0, 1, or 2;

[0028] p is independently 0 or 1; and

[0029] q is independently 0, 1, 2, or 3;

[0030] or having a structure according to Formula (B),

[0031]

[0032] or is a pharmaceutically acceptable salt thereof, wherein

[0033] R2is independently H, OH, or (CH2)PCO2R5;

[0034] R4is independently Ci-Ce alkyl, 1- to 6-membered heteroalkyl, or X1-R6, or two R4on adjacent carbons combine to form a heteroaryl moiety, or one R4combines with R7Bto form a heteroaryl moiety;

[0035] X1is independently a covalent bond, O, or CH2;

[0036] R5is independently H or Ci-Ce alkyl;

[0037] R6is independently Ce-Cio aryl or 5- to 10-membered heteroaryl;

[0038] each R7Bis independently H or Ci-Ce alkyl, or R7Bcombines with R4to form a heteroaryl moiety;

[0039] L2is independently a covalent bond, C(O), NR7B, C(O)NR7B, or NR7BC(O);

[0040] Cy is independently C5-C7 cycloalkyl, 5- to 7-membered heterocyclyl, 5- to 6-membered heteroaryl or phenyl;

[0041] each of n and 0 is independently 0, 1, or 2; and

[0042] p is independently 0, 1, 2, or 3.

[0043] BRIEF DESCRIPTION OF THE FIGURES

[0044] Fig. 1 depicts a study of Compound (4) and the peptide angiotensin-(l-7) in a diabetic mouse model.

[0045] Fig. 2 depicts a study of Compound (3)-trans and angiotensin-(l-7) in Mesangial cells.

[0046] Attorney Docket No.: 778138: CST9-008PC

[0047] Fig. 3 depicts receptor-binding studies of Compound (5).

[0048] Fig. 4 depicts studies of compounds in an Ussing chamber. Fig. 4A-C depicts studies of compounds of Formula (A) (labeled with M13(2)12 (Compound (34)), M13 (Compound (4)), M13(2)l (Compound (9)), M13(2)4 (Compound (33)), M13(2)9 (Compound (5)), and Ml 3(2)20 (Compound (1))), and compounds of Formula (B) (labeled with M13(2)13 (Compound (35)) and M13(2)15 (Compound (36))) in an Ussing chamber. Fig. 4D+E depicts studies of compounds of Formula (A) (labeled with M13 (Compound (4)) and Ml 3(2)20 (Compound (1))), endogenous agonist (labeled with EA) and solvent in an Ussing chamber.

[0049] Fig. 5 shows graphs of percent split formation upon administration of angiotensin-(l-7) in a human skin organ culture (HSOC), by either supplementation in the medium or injection. Split formation was measured and plotted relative to concentration of angiotensin-(l-7), for example, from 0.01 pM to 1 pM or 100 pM. As a positive control, scFv to autoantibodies was used as a positive control. Fig. 5A shows percent split formation at various concentrations of angiotensin-(l-7) from 0.01 pM to 100 pM supplemented in HSOC medium in HSOC. Fig. 5B shows percent split formation at various concentrations of angiotensin-(l-7) from 0.01 pM to 100 pM injected in HSOC. Fig. 5C shows percent split formation at various concentrations of angiotensin-(1-7) from 0.01 pM to 1 pM injected in HSOC.

[0050] Fig. 6 shows histopathologic analysis of split formation in a human skin model. While an scFv positive control against desmoglein 1 and 3 autoantibodies, shows pronounced split formation in the microscopic images, an angiotensin-(l-7) injected sample shows decreased split formation, indicative of amelioration of pemphigus and pemphigoid disease. Angiotensin-(l-7) treatment resulted in a significant reduction in split formation.

[0051] Fig. 7 demonstrates the reduction of skin lesions in a preclinical model of a blistering skin disease by treatment with angiotensin-(l-7) and a small compound of the invention. Agents were administered daily from day 3 and the affected skin area was measured. Fig. 7A shows the results on the last treatment day. Fig. 7B shows the reduction of affected skin area compared to the control over time for the small compound.

[0052] Attorney Docket No.: 778138: CST9-008PC

[0053] DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

[0054] Before the present invention is described in detail below, it is to be understood that this invention is not limited to the particular methodology, protocols and reagents described herein as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0055] In the following, the elements of the present invention will be described. These elements are listed with specific embodiments. However, it should be understood that they might be combined in any manner and in any number to create additional embodiments. The variously described examples and preferred embodiments should not be construed to limit the present invention to only the explicitly described embodiments. This description should be understood to support and encompass embodiments, which combine the explicitly described embodiments with any number of the disclosed and / or preferred elements. Furthermore, any permutations and combinations of all described elements in this application should be considered disclosed by the description of the present application unless the context indicates otherwise. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.

[0056] Throughout this specification and the claims that follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", are to be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integer or step. In preferred embodiments, "comprise" can mean "consist of'. As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents, unless the content clearly dictates otherwise. Whenever the conjunction "and / or" is used herein, the preferred embodiment is "and", unless indicated otherwise.

[0057] Several documents are cited throughout the text of this specification. Each of the documents cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc.) are hereby incorporated by reference in their entirety.

[0058] Attorney Docket No.: 778138: CST9-008PC

[0059] The invention in general

[0060] The invention relates to a method of treating a blistering skin disease comprising administering a compound having the structure according to Formula (A) to a subject suffering from the blistering skin disease. The invention also relates to a compound having the structure according to Formula (A) for use in treating a blistering skin disease. Also, the invention relates to the use of compound having the structure according to Formula (A) in the manufacture of a medicament for treating an autoimmune blistering skin disease.

[0061] Blistering skin disease

[0062] The term “blistering skin disease” refers to a disease characterized by the formation of blisters (vesicles or bullae) on the skin and / or mucous membranes. These blisters result from damage or separation within different layers of the skin which may be due to various causes, e.g. autoimmune reactions, genetic mutations, infections, or external factors like burns or allergic reactions. There are two main groups of blistering skin diseases: immunobullous and nonimmunobullous skin diseases.

[0063] The term “immunobullous skin disease” refers to autoimmune diseases in which the body’s immune system (in particular autoantibodies) mistakenly attacks components of the skin and sometimes also mucous membranes, i.e. the lining inside mouth, nose, and other parts of the body. These diseases specifically involve immune-mediated damage to structural proteins that hold skin layers together. The attack causes blisters (small pockets of body fluid within the upper layers of the skin) to form. The term is used herein synonymously with “autoimmune blistering skin disease”.

[0064] The main groups of immunobullous blistering skin disease are pemphigus and pemphigoid. As such, in a preferred embodiment, the immunobullous blistering skin disease is pemphigus or pemphigoid.

[0065] The term “pemphigus” refers to blistering disorders caused by autoantibodies such as desmoglein 1 and desmoglein 3 that recognize components of the epidermis and lead to disruption of the intercellular junctions, loss of integrity and formation of blisters in the epidermis that break easily. The pemphigus is preferably selected from the group consisting of pemphigus vulgaris, pemphigus foliaceus, IgA pemphigus, paraneoplasticAttorney Docket No.: 778138: CST9-008PC pemphigus, pemphigus vegetans, drug-induced pemphigus, pemphigus erythematosus (Senear-Usher syndrome), endemic pemphigus (fogo selvagem), benign familial pemphigus (Hailey-Hailey disease), and combinations thereof. More preferably, the pemphigus is pemphigus vulgaris.

[0066] The combination may be sequential or concurrent, preferably it is concurrent.

[0067] These specific diseases can be described as follows:

[0068] In pemphigus vulgaris, blisters are formed in mouth and other mucous membranes causing red and white fluid-filled blisters or open sores, and blisters on skin near groin and legs.

[0069] In pemphigus foliaceus, red to purple blisters develop on scalp, face, neck and back, but rarely mouth. The epidermis layer is affected and small blisters form in groups that break easily to form crusty lesions spreading over large areas of skin.

[0070] Pemphigus vegetans forms thick lesions, typically in skin folds including groin and armpit regions.

[0071] Paraneoplastic pemphigus is the rarest form of pemphigus in cancer patients that causes severe oral blisters.

[0072] Endemic pemphigus is a form of pemphigus foliaceus that occurs most commonly in South and Central America, for example, Brazil.

[0073] IgA pemphigus causes lesions in the skin of trunk, upper and lower extremities, armpit and groin. It affects mucous membranes infrequently. IgA pemphigus manifests as blisters, pustules, erythema, erosions, and vegetating lesions. Flaccid vesicles and pustules form first, which then rupture to form erosions and crusted plaques, and the eruptions follow an annular pattern.

[0074] Benign familial pemphigus is an inherited skin disorder that arises due to a mutation in a gene ATP2C1 that encodes SPCA1 (Secretory Pathway Calcium / manganese-ATPase), a calcium and manganese pump. Skin cells or keratinocytes are packed together by structures known as desmosomes that do not assemble in the absence of sufficient calcium as in benign familial pemphigus. Benign familial pemphigus starts as a painful crusted skin rash, typically in the armpit, groin, neck, under breasts and in the buttocks, in skin folds and creases. As the lesions get bigger, the center clears leaving a typical ring, and the lesions grow thicker which then causes maceration and painful cracks in the skin. It may

[0075] Attorney Docket No.: 778138: CST9-008PC sometimes involve mucous membranes or cause white bands on the fingernails and pits in the palms.

[0076] Drug-induced pemphigus: Some medications, for example, antibiotics or blood pressure medication, might result in blistering, sometimes months later.

[0077] Pemphigus erythematosus or Senear-Usher syndrome sometimes presents with lupus and causes blisters on upper back, chest, cheeks and scalp that develop into red, scaly lesions.

[0078] The term “pemphigoid” refers to diseases causing blisters in a skin layer between the dermis and epidermis (which usually do not break easily), sometimes having the appearance of hives or eczema. Autoantibodies, for example, anti-BPA2 and anti-BPA1, are directed against the basal layer of the epidermis and mucous membranes, causing skin cells to separate from one another and cause fluid accumulation between skin layers forming blisters sometimes covering a large area of skin. Pemphigoid diseases can be distinguished from pemphigus, by a negative Nikolsky sign, i.e. friction of non-lesional skin does not lead to intra epidermal disruption and visible erosion. Pemphigoid is preferably selected from the group consisting of bullous pemphigoid (BP), mucous membrane pemphigoid (MMP, or cicatricial pemphigoid), pemphigoid gestationis, epidermolysis bullosa acquisita (EBA), linear IgA disease, anti-laminin gl / anti-p200 pemphigoid, lichen planus pemphigoides, pemphigoid disease characterised by renal insufficiency, and combinations thereof. More preferably, it is BP or EBA. The combination may be sequential or concurrent, preferably it is concurrent.

[0079] These specific diseases can be described as follows:

[0080] Bullous pemphigoid (BP) is a rare disease that causes large, fluid-filled blisters on the skin of the lower abdomen, upper thighs or armpits. Autoantibodies are targeted towards the fibers that connect epidermis to dermis layer of the skin. BP is common in adults over 60. Bullous pemphigoid may be triggered by medications, e.g., etanercept, sulfasalazine, furosemide and penicillin, or light and radiation, e.g., ultraviolet light or radiation therapy, and medical conditions, e.g., psoriasis, lichen planus, diabetes, rheumatoid arthritis, ulcerative colitis and multiple sclerosis.

[0081] Mucous Membrane pemphigoid (MPP) is a group of rare chronic autoimmune disorders characterized by blistering lesions that affect the various mucous membranes of the body, for example, mucous membranes of the mouth and eyes. In some cases, blistering lesions also form on the skin, especially in the head and neck area. In addition,Attorney Docket No.: 778138: CST9-008PC mucous membranes of the nose, throat, genitalia, and anus may be affected. As lesions heal, there may be scarring, which leads to serious complications affecting the eyes and throat.

[0082] Pemphigoid gestationis (previously called herpes gestationis) is a rare dermatosis of pregnancy. It is a bullous autoimmune, sub-epidermal dermatosis, clinically and pathogenetical ly similar to bullous pemphigoid.

[0083] Epidermolysis bullosa acquisita (EBA) is characterized by autoantibodies against type VII collagen. Clinically, EBA can either be the classic form or an inflammatory variant. The classic mechanobullous form presents with tense blisters and skin fragility preferentially localised to the extensor skin surfaces at trauma-prone areas. The inflammatory subtype can resemble bullous pemphigoid or mucous membrane pemphigoid.

[0084] Linear IgA disease is named for its main immunopathological feature, which is the linear binding of IgA at the dermal-epidermal junction. It is the most common pemphigoid disorder in children and has two peaks of onset- before the age of 5 years and after the age of 60 years. The major target antigen is BP180, another is BP230. Anti-laminin gl / anti-p200 pemphigoid clinically mimics bullous pemphigoid, although patients tend to be younger and concurrent psoriasis is seen in about a third of cases. Diagnosis is made by detection of autoantibodies against 200 kDa protein laminin v 1 (also referred to as p200 protein) of the dermal-epidermal junction. Lichen planus pemphigoides always arises in conjunction with lichen planus. The main target antigen is BP180, another is BP230. It affects fairly young patients (mean age of onset 40-50 years), mainly arises on the limbs, and preferentially targets C-terminal epitopes in the immunodominant NC16A domain.

[0085] Pemphigoid disease characterized by renal insufficiency is rare and characterized by autoantibodies against the a5 chain of type IV collagen.

[0086] The term “nonimmunobullous skin disease” refers to blistering skin diseases not caused by autoimmune reactions. Instead, they result from e.g. genetic defects, infections, physical injury, or toxic exposures that lead to mechanical separation or damage within the skin layers, forming blisters. They can be distinguished from immunobullous skin disease by the absence of autoantibodies, specifically to structural proteins that hold skin layers together. The term may be used synonymously with “non-autoimmune blistering skin disease”.

[0087] Attorney Docket No.: 778138: CST9-008PC

[0088] In a preferred embodiment, the nonimmunobullous blistering skin disease is associated with an infection, is associated with a physical trauma, is associated with a drug, is associated with dermatitis, is a metabolic disorder or is a genetic disorder. The genetic disorder preferably is epidermolysis bullosa (EB).

[0089] A nonimmunobullous blistering skin disease associated with infection is usually due to an infection or damage due to the infection or the resulting immune response. The infection is e.g. be a viral infection (e.g. by Herpes simplex virus, Varicella-zoster virus, Vaccinia virus, Enterovirus (e.g. 71) or Coxsackievirus (e.g. Al 6)) where the disease may be a result of viral cytopathic effects, viral replication or immune-mediated inflammation. The infection may also be a bacterial infection, e.g. by Staphylococcus aureus, Streptococcus pyogenes, or both, leading to Impetigo contagiosa. The infection may also be a fungal infection (usually by a dermatophype, e.g. Trichophyton mentagrophytes), where the fungal pathogen may disrupt the skin barrier, leading to blister formation. The blisters can arise due to inflammatory response, keratinocyte damage, or superficial epidermal cleavage.

[0090] Skin blistering due to physical trauma is the formation of fluid-filled blisters on the skin as a result of external physical forces that cause the skin layers to separate, typically due to friction (like rubbing), pressure, or shear stress. The physical trauma may be a mechanical, thermal or cold trauma.

[0091] The nonimmunobullous blistering skin disease associated with a drug may be a fixed drug eruption (FDE) or toxic epidermal necrolysis (TEN). FDE is a cutaneous drug reaction characterized by the recurrence of skin or mucosal lesions at the same site each time the offending drug is taken. TEN is a life-threatening mucocutaneous reaction characterized by widespread skin detachment, epidermal necrosis, and mucosal involvement.

[0092] The dermatitis may be contact dermatitis or phytophotodermatitis. Contact dermatitis is an inflammatory skin condition caused by direct contact with an irritant or allergen, leading to redness, itching, and sometimes blistering at the site of exposure. Phytophotodermatitis is a skin reaction that occurs when certain plant chemicals (furocoumarins or psoralens) come into contact with the skin and then the skin is exposed to sunlight or UV radiation. This leads to an inflammatory reaction that causes blisters, redness, and pigmentation changes.

[0093] Attorney Docket No.: 778138: CST9-008PC

[0094] The metabolic disorder may be porphyria, specifically porphyria cutanea tarda. Porphyria cutanea tarda (PCT) is the most common type of porphyria, a group of disorders caused by abnormalities in the production of heme (the iron-containing component of hemoglobin). They primarily affect the skin, causing blistering, fragility, and hyperpigmentation, particularly in areas exposed to sunlight.

[0095] The genetic disorder may be epidermolysis bullosa (EB) or incontinentia pigmenti. EB is a group of rare, inherited skin disorders characterized by blistering and fragility of the skin and mucous membranes. This condition results from defects in the proteins that normally help hold the skin layers together, leading to easy blister formation in response to minimal friction or trauma. These proteins are structural proteins critical for skin integrity, including keratin (in the epidermis), collagen (in the dermis), and other adhesion proteins. They are generally responsible for the anchoring and attachment of the epidermis to the dermis. Incontinentia pigmenti is a rare X-linked genetic disorder that often manifests in the blistering stage, where skin lesions appear as vesicles (blisters) on the skin, typically within the first few weeks of life. These blisters are followed by other skin changes like papules, pigmentation alterations, and scarring as the disease progresses.

[0096] Treating

[0097] As used herein, the term “treat,” “treatment,” or “treating” refers to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of and / or reduce incidence of one or more symptoms or features of the skin blistering disease. The treatment is achieved by administering a therapeutically effective amount of the small compound of the invention.

[0098] The at least one symptom of the blistering skin disease, wherever referred to herein, may be selected from the group consisting of ulcers, blisters, eczema, hives, and combinations thereof. Preferably, the at least one symptom comprises ulcers and / or blisters, more preferably blisters. In a preferred embodiment, the ulcers and / or the blisters are on skin or mucous membrane, preferably on skin. The mucous membrane may be of mouth, nose, throat, eyes, or genitals.

[0099] Attorney Docket No.: 778138: CST9-008PC

[0100] Subject

[0101] The subject is a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cattle, swine, sheep, horse or primate), preferably a human. In a preferred embodiment, the subjection is suffering from the blistering skin disease, i.e. the subject has been diagnosed with or displays one or more symptoms of the disease, in particular skin blistering.

[0102] Administration

[0103] In a preferred embodiment, the small compound of the invention is administered, preferably at an effective dose periodically at an administration interval, such that at least one symptom or feature of the blistering skin disease is reduced in intensity, severity, duration, or frequency or has delayed onset, preferably to a control subject suffering from the same disease that is not treated.

[0104] The administration may be parenteral, rectal, oral, or a combination thereof, preferably it is oral. The parenteral administration may be intravenous, subcutaneous, inhalation, intradermal, transdermal, and / or transmucosal administration.

[0105] Combination Therapies

[0106] The small compound of the invention may be used as a part of a combination therapy. Specifically, it may be administered prior to, concurrently with, or subsequent to one or more additional medications. It is contemplated that any known medication for the treatment of the blistering skin disease may be used with the small compound of the invention. Exemplary therapies that may be used include, but are not limited to sartanes (and prodrugs thereof) and / or medications that control the immune response, prevent secondary infections, promote wound healing and / or minimize pain and scarring. Exemplary therapies are:

[0107] Nutritional support, pain control, or wound care.

[0108] For autoimmune blistering skin diseases, first-line treatments such as systemic corticosteroids (e.g., prednisone) or topical steroids; steroid-sparing immunosuppressants, such as Azathioprine, Mycophenolate mofetil, Methotrexate and Cyclophosphamide; biologies, such as an anti-CD20 monoclonal antibody (e.g. Rituximab, for example for treating pemphigus vulgaris) or IVIG (intravenous immunoglobulin); Dapsone or Nicotinamide + tetracycline.

[0109] Attorney Docket No.: 778138: CST9-008PC

[0110] For infectious causes, antivirals such as acyclovir or valacyclovir, or antibiotics for bacterial infections.

[0111] Sartanes are pharmaceuticals that bind to and inhibit the angiotensin II receptor type 1 (AT₁) and thereby block the arteriolar contraction and sodium retention effects of renin-angiotensin system. They are also known as angiotensin II receptor blockers (ARBs), as angiotensin II receptor type 1 antagonists, and as angiotensin receptor blockers. Exemplary sartanes are azilsartan (prodrug: azilsartanmedoxomil), candesartan (prodrug: candesartancilexetil), eprosartan, fimasartan, irbesartan, losartan, milfasartan, olmesartan (prodrug: olmesartanmedoxomil), pomisartan, pratosartan, ripisartan, saprisartan, tasosartan,

[0112] telmisartan and valsartan.

[0113] The additional medication(s) may be provided and / or administered with the small compound of the invention in the same pharmaceutical composition or separately (e.g. provided as a kit).

[0114] Pharmaceutical Composition

[0115] The small compound of the invention, preferably in a pharmaceutically acceptable form, may be comprised in a pharmaceutical composition, generally in a therapeutically effective amount. A pharmaceutically acceptable form of a compound includes any pharmaceutically acceptable salts, hydrates, solvates, isomers, prodrugs, and isotopically labeled derivatives thereof; preferably it is a pharmaceutically acceptable salt. Examples of such salts are acid addition salts formed with inorganic acids, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like. Salts may also be formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, and the like. Salts formed from a cationic material may utilize the conjugate base of these inorganic and organic acids. Salts may also be formed with polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel and the like or with an organic cation formed from N, N'-dibenzylethylenediamine or ethylenediamine, or combinations thereof (e.g., a zinc tannate salt). The non-toxic, physiologically acceptable salts are preferred. The salts can be formed by conventional means such as by reacting the free acid or free base forms ofAttorney Docket No.: 778138: CST9-008PC the product with one or more equivalents of the appropriate acid or base in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying, or by exchanging the cations of an existing salt for another cation on a suitable ion exchange resin.

[0116] Preferably, the pharmaceutical composition comprises a pharmaceutically acceptable excipient or carrier, which are interchangeable terms herein. Generally, the excipient or carrier is an ingredient used in the practice of formulating a safe and effective pharmaceutical composition, specifically the terms refer to any substance that is acceptable for use in pharmaceutical applications from a toxicological perspective and does not adversely interact with the active ingredient. Accordingly, pharmaceutically acceptable excipients or carriers are those that are compatible with the other ingredients in the composition and are biologically acceptable. Pharmaceutically acceptable excipients or carriers include, but are not limited to, glycerol, water, saline, ethanol and other pharmaceutically acceptable salt solutions such as phosphates and salts of organic acids. Examples of these and other pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1991, Mack Publication Co., New Jersey).

[0117] Pharmaceutical compositions that are useful in the methods of the invention may be formulated for inhalational, oral, rectal, vaginal, parenteral, topical, transdermal, pulmonary, intranasal, buccal, ophthalmic, intrathecal, transdermal, nasal, inhalation, endotrache, intravenous, subcutaneous, intramuscular, epidural injection, or another route of administration, preferably for oral administration.

[0118] For any of these routes of administration, the pharmaceutical composition may be formulated for administration in solid or liquid form, e.g., drenches (aqueous or nonaqueous solutions or suspensions), tablets, sterile solutions, suspensions, sustained-release formulations, cream, ointment, controlled-release patch or spray. Tablets are preferred, in particular for oral administration.

[0119] Small compound of the invention

[0120] The small compound used in the invention is a compound having the structure according to Formula (A) or according to Formula (B). It is a ligand for Mas receptor (or G Protein-Coupled Mas Receptor, Uniprot identifier for human Mas receptor: P04201) and / or for Mas-related G-protein coupled receptor member D (MrgD receptor, Uniprot identifier for human MrgD receptor: Q8TDS7). Mas receptors are G-protein

[0121] Attorney Docket No.: 778138: CST9-008PC coupled receptor containing seven transmembrane spanning regions. “Ligand” with respect to the small compound of the invention and the above receptors is used interchangeably herein with “agonist”, which means that the small compound of the invention is capable of activating Mas receptor and / or MrgD receptor.

[0122] The invention features the use of compounds of Formulas (A) (e.g., Formulas (I)-(X)) and (B), including subformulas thereof as well as certain specifically described compounds (e.g., Compounds (l)-(36)), as well as pharmaceutically acceptable forms thereof. Compounds described herein are suitable for pharmaceutical compositions and methods of use (e.g., methods of treating diseases and disorders), including the nonlimiting exemplary embodiments described herein.

[0123] That is, certain exemplary formulas and compounds are described herein. Also provided herein are exemplary embodiments of structural features which may be present in any formula described herein. Any exemplary embodiment of a structural feature may occur in combination with any other exemplary structural feature described herein. Further, and unless otherwise indicated herein, any description of a formula or compound also includes any pharmaceutically acceptable forms of the compound, including but not limited to any pharmaceutically acceptable salts, hydrates, solvates, isomers, polymorphs, prodrugs, and isotopically labeled derivatives of disclosed formulas and compounds.

[0124] When any variable occurs more than one time in any constituent or in any formula, its definition in each occurrence is independent of its definition at every other occurrence (e.g., in N(R9)2, each R9may be the same or different than the other). Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.

[0125] Any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms. In particular, compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of the formula. Thus, any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof. Furthermore, certain structures may exist as geometric isomers (i.e., cis and trans isomers), as tautomers, or as atropisomers. Additionally, any formula givenAttorney Docket No.: 778138: CST9-008PC herein is intended to embrace hydrates, solvates, and polymorphs of such compounds, and mixtures thereof.

[0126] Compounds described herein can comprise an asymmetric atom (also referred as a chiral center), and some of the compounds can comprise one or more asymmetric atoms or centers, which can thus give rise to optical isomers (enantiomers) and diastereomers. The present teachings and compounds disclosed herein include such enantiomers and diastereomers, as well as the racemic and resolved, enantiomerically pure R and S stereoisomers, as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof. Optical isomers can be obtained in pure form by standard procedures known to those skilled in the art, which include, but are not limited to, diastereomeric salt formation, kinetic resolution, and asymmetric synthesis. The present teachings also encompass cis and trans isomers of compounds containing alkenyl moieties (e.g., alkenes and imines). It is also understood that the present teachings encompass all possible regioisomers, and mixtures thereof, which can be obtained in pure form by standard separation procedures known to those skilled in the art, and include, but are not limited to, column chromatography, thin-layer chromatography, and high-performance liquid chromatography.

[0127] Compounds described herein can comprise atoms that exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominately found in nature. The term “isotopologue” refers to a species that has the same chemical structure and formula as a specific compound provided herein, with the exception of the positions of isotopic substitution and / or level of isotopic enrichment at one or more positions, e.g., hydrogen vs. deuterium. The present invention is meant to include all suitable isotopic variations of the compounds of the compounds described herein. For example, different isotopic forms of hydrogen (H) include protium (1H), deuterium (2H), and tritium (3H), as well as compositions enriched in isotopologues of any compound described herein.

[0128] In embodiments, one or more of the hydrogens of the compounds described herein is replaced by a deuterium. When a position is designated as “H” or “hydrogen”, the position is understood to have hydrogen at its natural abundance isotopic composition. When a position is designated as “2H” or “deuterium”, the position is understood to have deuterium at an abundance that is at least 3340 times greater than the natural

[0129] Attorney Docket No.: 778138: CST9-008PC abundance of deuterium, which is 0.015% (i.e., the term “2H” or “deuterium” indicates at least 50.1% incorporation of deuterium). Accordingly, the invention also features compositions enriched in deuterated compounds.

[0130] In embodiments, compositions of any compound provided herein may have an isotopic enrichment factor for each deuterium present at a site designated as a potential site of deuteration on the compound of at least 3500 (52.5% deuterium incorporation), at least 4000 (60% deuterium incorporation), at least 4500

[0131] (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3

[0132] (99.5% deuterium incorporation).

[0133] Formula (A)

[0134] In preferred embodiments, the compound used according to the invention has a structure according to Formula (A),

[0135]

[0136] or a pharmaceutically acceptable salt thereof, wherein each of L1, L2, R1, R2, R3, R4, Cy, m, n, o, and q is independently according to any embodiment, or combination of embodiments, as described herein.

[0137] In preferred embodiments of Formula (A), R1is independently H or Ci-Ce alkyl; R2is independently H, OH, or (CH2)PCO2R5; R3is independently Ci-Ce alkyl, 1- to 6-membered heteroalkyl, or X^R6; R4is independently Ci-Ce alkyl, 1- to 6-membered heteroalkyl, or X1-R6, or two R4on adjacent carbons combine to form a heteroaryl moiety, or one R4combines with R7Bto form a heteroaryl moiety; L1is independently a covalent bond, C(O), C(O)NR7A, or NR7AC(O); X1is independently a covalent bond, O, or CH2;

[0138] R5is independently H or Ci-Ce alkyl; R6is independently Ce-Cio aryl or 5- to 10-membered heteroaryl; each R7Ais independently H or Ci-Ce alkyl; each R7Bis independently H or Ci-Ce alkyl, or R7Bcombines with R4to form a heteroaryl moiety;

[0139] Attorney Docket No.: 778138: CST9-008PC

[0140] X1is independently a covalent bond, O, or CH2; L2is independently a covalent bond, CH2, C(O), NR7B, C(O)NR7B, or NR7BC(O); Cy is independently C5-C10 cycloalkyl, 5-to 7-membered heterocyclyl, 5- to 6-membered heteroaryl or phenyl; each of n and 0 is independently 0, 1, or 2; and p is independently 0, 1, 2, or 3.

[0141] In preferred embodiments, L2is independently a covalent bond, C(O), NR7B, C(O)NR7B, orNR7BC(O).

[0142] In preferred embodiments, Cy is independently C5-C7 cycloalkyl, 5- to 7-membered heterocyclyl, 5- to 6-membered heteroaryl or phenyl. More preferred, Cy is C5-C7 cycloalkyl, in particular cyclohexyl, or phenyl.

[0143] Formula (I)

[0144] In preferred embodiments, the compound (A), i.e. the compound used according to the invention, has a structure according to Formula (I),

[0145]

[0146] or a pharmaceutically acceptable salt thereof, wherein each of L1, L2, R1, R2, R3, R4, Cy, m, n, and 0 is independently according to any embodiment, or combination of embodiments, as described herein.

[0147] In preferred embodiments of Formula (I), each of R1and R5is independently H or Ci-Ce alkyl; R2is independently H or (CH2)pCO2R5; R3is independently Ci-Ce alkyl, 1-to 6-membered heteroalkyl, or X’-R6; R4is independently Ci-Ce alkyl, 1- to 6-membered heteroalkyl, or X1-R6, or two R4on adjacent carbons combine to form a heteroaryl moiety, or one R4combines with R7Bto form a heteroaryl moiety; L1is independently a covalent bond, C(O), C(O)NR7A, or NR7AC(O); L2is independently a covalent bond, CH2, C(O), NR7B, C(O)NR7B, or NR7BC(O); R6is independently Ce-Cio aryl or 5- to 10-membered heteroaryl; each R7Ais independently H or Ci-Ce alkyl; each R7Bis independently H or Ci-Ce alkyl, or R7Bcombines with R4to form a heteroaryl moiety;

[0148] X1is independently a covalent bond, O, or CH2; Cy is independently C5-C10 cycloalkyl, 5- to 7-membered heterocyclyl, 5- to 6-membered heteroaryl or phenyl; each of m, n, and o is independently 0, 1, or 2; and p is independently 0 or 1.

[0149] Attorney Docket No.: 778138: CST9-008PC

[0150] In preferred embodiments, L2is independently a covalent bond, C(O), NR7B, C(O)NR7B, orNR7BC(O).

[0151] In preferred embodiments, Cy is independently C5-C7 cycloalkyl, 5- to 7-membered heterocyclyl, 5- to 6-membered heteroaryl or phenyl. More preferred, Cy is C5-C7 cycloalkyl, in particular cyclohexyl, or phenyl.

[0152] Formula (B)

[0153] In some embodiments, the compound used according to the invention has a structure according to Formula (B),

[0154]

[0155] or is a pharmaceutically acceptable salt thereof, wherein each of L2, R2, R4, Cy, n, 0, and p is independently according to any embodiment, or combination of embodiments, as described herein.

[0156] In embodiments of Formula (B), R2is independently H, OH, or (CH2)PCO2R5; R4is independently Ci-Ce alkyl, 1- to 6-membered heteroalkyl, or X1-R6, or two R4on adjacent carbons combine to form a heteroaryl moiety, or one R4combines with R7Bto form a heteroaryl moiety; X1is independently a covalent bond, O, or CH2; R5is independently H or Ci-Ce alkyl; R6is independently Ce-Cio aryl or 5- to 10-membered heteroaryl; each R7Bis independently H or Ci-Ce alkyl, or R7Bcombines with R4to form a heteroaryl moiety; L2is independently a covalent bond, C(O), NR7B, C(O)NR7B, or NR7BC(O); Cy is independently C5-C7 cycloalkyl, 5- to 7-membered heterocyclyl, 5- to 6-membered heteroaryl or phenyl; each of n and 0 is independently 0, 1, or 2; p is independently 0, 1, 2, or 3.

[0157] In preferred embodiments of Formula (B), R2is independently H, OH, or (CH2)PCO2R5; R4is independently Ci-Ce alkyl, 1- to 6-membered heteroalkyl, or X1-R6, or two R4on adjacent carbons combine to form a heteroaryl moiety; X1is independently a covalent bond, O, or CH2; R5is independently H or Ci-Ce alkyl; R6is independently Ce-Cio aryl or 5- to 10-membered heteroaryl; each R7Bis independently H or Ci-Ce alkyl;

[0158] L2is independently a covalent bond, C(O), NR7B, C(O)NR7B, or NR7BC(O); Cy is independently C5-C7 cycloalkyl, 5- to 7-membered heterocyclyl, 5- to 6-memberedAttorney Docket No.: 778138: CST9-008PC heteroaryl or phenyl, which is preferred; each of n and o is independently 0, 1, or 2; p is independently 0, 1, 2, or 3. Preferably, R2is independently H, OH, or CH2CO2R5; and 0 is 1. More preferred, R2is independently OH, or CH2CO2R5, p is 2, or 3, preferably 3, Cy is phenyl, and 0 is 1.

[0159] In further preferred embodiments of Formula (B), R2is independently H, OH, or CH2CO2R5; R4is independently Ci-Ce alkyl; R5is independently H or Ci-Ce alkyl; each R7Bis independently H or Ci-Ce alkyl; L2is independently a covalent bond, C(O), NR7B, C(O)NR7B, orNR7BC(O), the latter being preferred; Cy is independently C5-C7 cycloalkyl or phenyl, which is preferred; each of n and 0 is independently 0, 1, or 2, preferably, 0 is 1; and p is independently 0, 1, 2, or 3, preferably, p is 2 or 3. Preferably, R2is independently OH, or CH2CO2R5, p is 2, or 3, preferably 3, Cy is phenyl, and 0 is 1.

[0160] The following are embodiments of Formulae (A) and (B).

[0161] In embodiments R1is independently H. In embodiments R1is independently Ci-Ce alkyl. In embodiments R1is independently unsubstituted Ci-Ce alkyl. In embodiments R1is independently substituted Ci-Ce alkyl. In embodiments R5is independently H. In embodiments R5is independently Ci-Ce alkyl. In embodiments R5is independently unsubstituted Ci-Ce alkyl. In embodiments R5is independently substituted Ci-Ce alkyl. In embodiments, R2is independently H. In embodiments, R2is independently OH. In embodiments, R2is independently (CH2)PCO2R5. In embodiments, p is independently 0. In embodiments, p is independently 1. In embodiments R3is independently Ci-Ce alkyl. In embodiments R3is independently unsubstituted Ci-Ce alkyl. In embodiments R3is independently substituted Ci-Ce alkyl. In embodiments R3is independently 1- to 6-membered heteroalkyl. In embodiments R3is independently unsubstituted 1- to 6-membered heteroalkyl. In embodiments R3is independently substituted 1- to 6-membered heteroalkyl

[0162] In embodiments R3is independently X’-R6. In embodiments, X1is independently a covalent bond. In embodiments, R6is independently Ce-Cio aryl (e.g., phenyl) or 5- to 10-membered heteroaryl (e.g., indole). In embodiments, R6is unsubstituted. In embodiments, R6is substituted. In embodiments, X1is independently O. In embodiments, R6is independently Ce-Cio aryl (e.g., phenyl) or 5- to 10-membered heteroaryl (e.g., indole). In embodiments, R6is unsubstituted. In embodiments, R6is substituted. In embodiments, X1is independently CH2. In embodiments, R6is independently Ce-Cio aryl (e.g., phenyl) or 5- to 10-membered heteroaryl (e.g., indole). In embodiments, R6isAttorney Docket No.: 778138: CST9-008PC unsubstituted. In embodiments, R6is substituted. In embodiments, R4is independently Ci-Ce alkyl. In embodiments R4is independently unsubstituted Ci-Ce alkyl. In embodiments R4is independently substituted Ci-Ce alkyl. In embodiments R4is independently 1- to 6-membered heteroalkyl. In embodiments R4is independently unsubstituted 1- to 6-membered heteroalkyl. In embodiments R4is independently substituted 1- to 6-membered heteroalkyl. In embodiments R4is independently X’-R6. In embodiments, two R4on adjacent carbons combine to form a heteroaryl moiety (e.g., an indole). In embodiments, one R4combines with R7Bto form a heteroaryl moiety. In embodiments, L1is independently a covalent bond. In embodiments, L1is independently C(O). In embodiments, L1is independently C(O)NR7A. In embodiments, L1is independently NR7AC(O). In embodiments, L2is independently a covalent bond. In embodiments, L2is independently CH2. In embodiments, L2is independently C(O). In embodiments, L2is independently NR7B. In embodiments, L2is independently C(O)NR7B. In embodiments, L2is independently NR7BC(O). In embodiments, each R7Ais independently H. In embodiments, each R7Ais independently Ci-Ce alkyl. In embodiments R7Ais independently unsubstituted Ci-Ce alkyl. In embodiments R7Ais independently substituted Ci-Ce alkyl. In embodiments, each R7Bis independently H. In embodiments, each R7Bis independently Ci-Ce alkyl. In embodiments R7Bis independently unsubstituted Ci-Ce alkyl. In embodiments R7Bis independently substituted Ci-Ce alkyl. In embodiments, R7Bcombines with R4to form a heteroaryl moiety. In embodiments, Cy is independently C5-C10 cycloalkyl (e.g., cyclopentyl, cyclohexyl, or decahydronaphthalenyl). In embodiments, Cy is unsubstituted. In embodiments, Cy is substituted. In embodiments, Cy is independently C5-C7 cycloalkyl (e.g., cyclohexyl). In embodiments, Cy is unsubstituted. In embodiments, Cy is substituted. In embodiments, Cy is independently 5- to 7-membered heterocyclyl. In embodiments, Cy is unsubstituted. In embodiments, Cy is substituted. In embodiments, Cy is independently 5- to 6-membered heteroaryl. In embodiments, Cy is unsubstituted. In embodiments, Cy is substituted. In embodiments, Cy is independently phenyl. In embodiments, Cy is unsubstituted. In embodiments, Cy is substituted. In embodiments, m is independently 0. In embodiments, m is independently 1. In embodiments, m is independently 2. In embodiments, n is independently 0. In embodiments, n is independently 1. In embodiments, n is independently 2. In embodiments, 0 is independently 0. In embodiments, 0 is independently 1. In embodiments, 0 is

[0163] Attorney Docket No.: 778138: CST9-008PC independently 2. In embodiments, p is independently 0. In embodiments, p is independently 1. In embodiments, p is independently 2. In embodiments, p is independently 3. In embodiments, q is independently 0. In embodiments, q is independently 1. In embodiments, q is independently 2. In embodiments, q is independently 3.

[0164] In embodiments, each of R1and R5is independently H. In embodiments, m and n are both 0. In embodiments, one of m and n is 1, and the other is 0. In embodiments, R3is independently methyl and / or R4is independently methyl, isopropyl, or benzyl. In embodiments, L1is a covalent bond, o is 0, and R2is H. In embodiments, L1is NHC(O) and o is 1. In embodiments, L2is a covalent bond, o is 0, and R2is H. In embodiments, L2is CH2, o is 1, and R2is H. In embodiments, L2is NHC(O) and o is 1. In embodiments, L2is NR7B, o is 0, and R2is H. In embodiments, L2is NR7B, o is 0, and R2is H. In embodiments, L2is NR7B, o is 0, and R2is methyl. In embodiments, L2is NR7B, o is 1, and R2is H. In embodiments, R7Bis H, o is 0, and R2is H. In embodiments, R7Bis methyl, o is 0, and R2is H. In embodiments, R7Bis H, o is 0, and R2is methyl. In embodiments, R7Bis H, o is 1, and R2is H. In embodiments, Cy is phenyl. In embodiments, Cy is cyclohexyl. In embodiments, Cy is cyclopentyl. In embodiments, Cy is decahydronaphthalenyl.

[0165] In embodiments, non-hydrogen groups on different carbons of the cyclohexyl moiety substituted by -CO2R1are cis to each other (also referred to as a “czs-cyclohexyl”). In embodiments, non-hydrogen groups on different carbons of the cyclohexyl moiety substituted by -CO2R1are trans to each other (also referred to as a ‘7ra / ?.s-cyclohcxyl”). In embodiments where Cy is C5-C10 cycloalkyl (e.g., a cyclohexyl, a cyclopentyl, or decahydronaphthalene) or 5- to 7-membered heterocyclyl, non-hydrogen groups on different carbons of on a Cy moiety are cis to each other (also referred to as a “czs-Cy”). In embodiments where Cy is C5-C7 cycloalkyl (e.g., a cyclohexyl or a cyclopentyl) or 5-to 7-membered heterocyclyl, non-hydrogen groups on different carbons of on a Cy moiety are cis to each other (also referred to as a “czs-Cy”). In embodiments where Cy is C5-C10 cycloalkyl (e.g., a cyclohexyl, a cyclopentyl, or decahydronaphthalene) or 5- to 7-membered heterocyclyl, non-hydrogen groups on different carbons of a Cy moiety are trans to each other (also referred to as a “trazzs-Cy”). In embodiments where Cy is C5-C7 cycloalkyl (e.g., a cyclohexyl or a cyclopentyl) or 5- to 7-membered heterocyclyl, non-Attorney Docket No.: 778138: CST9-008PC hydrogen groups on different carbons of a Cy moiety are trans to each other (also referred to as a “trazzs-Cy”).

[0166] In embodiments, a compound of Formula (A), or any subformulas thereof, comprises a cz.s-cyclohcxyl and a cis-Cy (e.g., a cz.s-cyclohcxyl, a cz.s-cyclopcntyl, or a cz'.s-dccahydronaphthalcnyl). In embodiments, a compound of Formula (A), or any subformulas thereof, comprises a cz.s-cyclohcxyl and a cis-Cy (e.g., a cz.s-cyclohcxyl or a cz.s-cyclopcntyl).

[0167] In embodiments, a compound of Formula (A), or any subformulas thereof, comprises a Zrazz.s-cyclohcxyl and a trans-Cy (e.g., a Zrazz.s-cyclohcxyl, a Zrazz.s-cyclopcntyl, or a trans-decahydronaphthalenyl). In embodiments, a compound of Formula (A), or any subformulas thereof, comprises a Zrazz.s-cyclohcxyl and a trans-Cy (e.g., a trans-cyclohexyl or a Zrazz.s-cyclopcntyl). In embodiments, a compound of Formula (A), or any subformulas thereof, comprises a Zrazz.s-cyclohcxyl and a cis-Cy (e.g., a cz.s-cyclohcxyl, a cz.s-cyclopcntyl, or a cz'.s-dccahydronaphthalcnyl). In embodiments, a compound of Formula (A), or any subformulas thereof, comprises a Zrazz.s-cyclohcxyl and a cis-Cy (e.g., a cz.s-cyclohcxyl or a cz.s-cyclopcntyl). In embodiments, a compound of Formula (A), or any subformulas thereof, comprises a cz.s-cyclohcxyl and a trans-Cy (e.g., a trans-cyclohexyl, a Zrazz.s-cyclopcntyl, or a tzYzzz.s-dccahydronaphthalcnyl). In embodiments, a compound of Formula (A), or any subformulas thereof, comprises a cz.s-cyclohcxyl and a trans-Cy (e.g., a Zrazz.s-cyclohcxyl or a trazzs-cyclopentyl).

[0168] In embodiments, a compound of Formula (I), or any subformulas thereof, comprises a cz.s-cyclohcxyl and a cis-Cy (e.g., a cz.s-cyclohcxyl, a cz.s-cyclopcntyl, or a cz'.s-dccahydronaphthalcnyl). In embodiments, a compound of Formula (I), or any subformulas thereof, comprises a cz.s-cyclohcxyl and a cis-Cy (e.g., a cz.s-cyclohcxyl or a cz.s-cyclopcntyl). In embodiments, a compound of Formula (I), or any subformulas thereof, comprises a Zrazz.s-cyclohcxyl and a trans-Cy (e.g., a Zrazz.s-cyclohcxyl, a trans-cyclopentyl, or a tzYzzz.s-dccahydronaphthalcnyl). In embodiments, a compound of Formula (I), or any subformulas thereof, comprises a Zrazz.s-cyclohcxyl and a trans-Cy (e.g., a Zrazz.s-cyclohcxyl or a Zrazz.s-cyclopcntyl). In embodiments, a compound of Formula (I), or any subformulas thereof, comprises a Zrazz.s-cyclohcxyl and a cis-Cy (e.g., a cz.s-cyclohcxyl, a cz.s-cyclopcntyl, or a cz'.s-dccahydronaphthalcnyl). In embodiments, a compound of Formula (I), or any subformulas thereof, comprises a Zrazz.s-cyclohcxyl and a cis-Cy (e.g., a cz.s-cyclohcxyl or a cz.s-cyclopcntyl). In embodiments, a compound of

[0169] Attorney Docket No.: 778138: CST9-008PC

[0170] Formula (I), or any subformulas thereof, comprises a c / .s-cyclohcxyl and a trans-Cy (e.g., a tra / z.s-cyclohcxyl, a trans-cycl openly 1, or a tra / z.s-dccahydronaphlhalcnyl). In embodiments, a compound of Formula (I), or any subformulas thereof, comprises a ciscyclohexyl and a trans-Cy (e.g., a Zrazz.s-cyclohcxyl or a trazzs-cyclopentyl).

[0171] In embodiments, a compound of Formula (B), or any sub formulas thereof, comprises a c / .s-cyclohcxyl and a cis-Cy (e.g., a c / .s-cyclohcxyl or a czs-cyclopentyl). In embodiments, a compound of Formula (B), or any subformulas thereof, comprises a Zrazz.s-cyclohcxyl and a trans-Cy (e.g., a Zrazz.s-cyclohcxyl or a Zra / z.s-cyclopcntyl). In embodiments, a compound of Formula (B), or any subformulas thereof, comprises a Zrazz.s-cyclohcxyl and a cis-Cy (e.g., a c / .s-cyclohcxyl or a c / .s-cyclopcnlyl). In embodiments, a compound of Formula (B), or any sub formulas thereof, comprises a ciscyclohexyl and a trans-Cy (e.g., a Zrazz.s-cyclohcxyl or a trazzs-cyclopentyl).

[0172] Formulas (I-A to I-G)

[0173] In preferred embodiments, a compound of Formula (I) has a structure according to Formula (I-A),

[0174]

[0175] or a pharmaceutically acceptable salt thereof, wherein each of R1, R2, R3, R4, Cy, m, n, and o is independently according to any embodiment, or combination of embodiments, as described herein.

[0176] In embodiments, the substituents on the cyclohexyl moiety are trans to each other, e.g., according to Formula (I-A’),

[0177]

[0178] Attorney Docket No.: 778138: CST9-008PC or a pharmaceutically acceptable salt thereof, wherein each of R1, R2, R3, R4, Cy, m, n, and o is independently according to any embodiment, or combination of embodiments, as described herein.

[0179] In embodiments where Cy is C5-C10 cycloalkyl (e.g., a cyclohexyl, a cyclopentyl, or decahydronaphthalenyl) or 5- to 7-membered heterocyclyl, non-hydrogen groups on different carbons of on a Cy moiety are cis to each other (also referred to as a “czs-Cy”).

[0180] In embodiments where Cy is C5-C7 cycloalkyl (e.g., a cyclohexyl or a cyclopentyl) or 5- to 7-membered heterocyclyl, non-hydrogen groups on different carbons of on a Cy moiety are cis to each other (also referred to as a “czs-Cy”). In embodiments where Cy is C5-C10 cycloalkyl (e.g., a cyclohexyl, a cyclopentyl, or decahydronaphthalenyl) or 5- to 7-membered heterocyclyl, non-hydrogen groups on different carbons of a Cy moiety are trans to each other (also referred to as a ‘7ra / ?.s -Cy”).

[0181] In embodiments where Cy is C5-C7 cycloalkyl (e.g., a cyclohexyl or a cyclopentyl) or 5-to 7-membered heterocyclyl, non-hydrogen groups on different carbons of a Cy moiety are trans to each other (also referred to as a “ / razz.s-Cy”).

[0182] In embodiments, the substituents on the cyclohexyl moiety are cis to each other, e.g., according to Formula (I-A”),

[0183]

[0184] or a pharmaceutically acceptable salt thereof, wherein each of R1, R2, R3, R4, Cy, m, n, and 0 is independently according to any embodiment, or combination of embodiments, as described herein.

[0185] In embodiments where Cy is C5-C10 cycloalkyl (e.g., a cyclohexyl, a cyclopentyl, or a decahydronaphthalenyl) or 5- to 7-membered heterocyclyl, non-hydrogen groups on different carbons of on a Cy moiety are cis to each other (also referred to as a “czs-Cy”). In embodiments where Cy is C5-C7 cycloalkyl (e.g., a cyclohexyl or a cyclopentyl) or 5-to 7-membered heterocyclyl, non-hydrogen groups on different carbons of on a Cy moiety are cis to each other (also referred to as a “czs-Cy”). In embodiments where Cy is C5-C10 cycloalkyl (e.g., a cyclohexyl, a cyclopentyl, or a decahydronaphthalenyl) or 5- to 7-membered heterocyclyl, non-hydrogen groups on different carbons of a Cy moiety areAttorney Docket No.: 778138: CST9-008PC trans to each other (also referred to as a “trans-Cy”. In embodiments where Cy is C5-C7 cycloalkyl (e.g., a cyclohexyl or a cyclopentyl) or 5- to 7-membered heterocyclyl, nonhydrogen groups on different carbons of a Cy moiety are trans to each other (also referred to as a “trans-Cy”).

[0186] In preferred embodiments, a compound of Formula (I) has a structure according to Formula (I-B),

[0187]

[0188] or a pharmaceutically acceptable salt thereof, wherein each of R1and R4is independently according to any embodiment as described herein.

[0189] In preferred embodiments, in the compounds of Formula (I-B), (I-B’), and (I-B”), R4is independently Ci-Ce alkyl, 1- to 6-membered heteroalkyl, or X1-R6; R6is independently Ce-Cio aryl or 5- to 10-membered heteroaryl; and X1is independently a covalent bond, O, or CH2.

[0190] In more preferred embodiments, in the compound of Formula (I-B), R4is independently Ci-Ce alkyl, or X’-R6, most preferred X’-R6; R6is independently Ce-Cio aryl, most preferred phenyl; and X1is independently a covalent bond, or CH2, CH2 being most preferred.

[0191] Preferably, the pharmaceutically acceptable salt is the sodium salt, or the disodium salt, respectively.

[0192] In embodiments, the substituents on an individual cyclohexyl moiety are cis to each other. In embodiments, the substituents on an individual cyclohexyl moiety are trans to each other. In embodiments, the substituents on each cyclohexyl moiety are cis to each other. In embodiments, the substituents on each cyclohexyl moiety are trans to each other. In embodiments, the substituents on one cyclohexyl moiety are trans to each other, and the substituents on the other cyclohexyl moiety are cis to each other.

[0193] Attorney Docket No.: 778138: CST9-008PC

[0194] In embodiments, a compound of Formula (I) has a structure according to Formula (I-B’),

[0195]

[0196] or a pharmaceutically acceptable salt thereof, wherein R4is independently according to any embodiment as described herein.

[0197] In embodiments, a compound of Formula (I) has a structure according to Formula (I-B”),

[0198]

[0199] or a pharmaceutically acceptable salt thereof, wherein R4is independently according to any embodiment as described herein.

[0200] In embodiments, the substituents on an individual cyclohexyl moiety are trans to each other.

[0201] In embodiments, a compound of Formula (I) has a structure according to Formula (I-C),

[0202]

[0203] or a pharmaceutically acceptable salt thereof, wherein each of R3and p is independently according to any embodiment, or combination of embodiments described herein. In embodiments, p is independently 0 or 1.

[0204] In embodiments, the substituents on the cyclohexyl moiety are cis to each other. In embodiments, the substituents on the cyclohexyl moiety are trans to each other. InAttorney Docket No.: 778138: CST9-008PC embodiments, substituents on adjacent carbons of a cyclohexyl ring are trans to each other, e.g., according to Formula (I-C ’),

[0205]

[0206] or a pharmaceutically acceptable salt thereof, wherein each of R3and p is independently according to any embodiment, or combination of embodiments described herein. In embodiments, p is independently 0 or 1.

[0207] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are cis to each other e.g., according to Formula (I-C”),

[0208]

[0209] or a pharmaceutically acceptable salt thereof, wherein each of R3and p is independently according to any embodiment, or combination of embodiments described herein. In embodiments, p is independently 0 or 1.

[0210] In embodiments, a compound of Formula (I) has a structure according to Formula (I-D),

[0211]

[0212] or a pharmaceutically acceptable salt thereof, wherein each of R3, R4, m, and n is independently according to any embodiment, or combination of embodiments described herein. In embodiments, each of m and n is independently 0 or 1. Where m is 0, a hydrogen is located at that position of the phenyl ring.

[0213] Attorney Docket No.: 778138: CST9-008PC

[0214] In embodiments, the substituents on the cyclohexyl moiety are cis to each other. In embodiments, the substituents on the cyclohexyl moiety are trans to each other. In embodiments, substituents on adjacent carbons of a cyclohexyl ring are cis to each other, e.g., according to Formula (I-D’),

[0215]

[0216] or a pharmaceutically acceptable salt thereof, wherein each of R3, R4, m, and n is independently according to any embodiment, or combination of embodiments described herein. In embodiments, each of m and n is independently 0 or 1. Where m is 0, a hydrogen is located at that position of the phenyl ring.

[0217] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are trans to each other, e.g., according to Formula (I-D”),

[0218]

[0219] or a pharmaceutically acceptable salt thereof, wherein each of R3, R4, m, and n is independently according to any embodiment, or combination of embodiments described herein. In embodiments, each of m and n is independently 0 or 1. Where m is 0, a hydrogen is located at that position of the phenyl ring.

[0220] In embodiments, a compound of Formula (I) has a structure according to Formula (I-E),

[0221]

[0222] or a pharmaceutically acceptable salt thereof, wherein each of R4and n is independently according to any embodiment, or combination of embodiments described herein. In embodiments, n is 0 or 1.

[0223] Attorney Docket No.: 778138: CST9-008PC

[0224] In embodiments, a compound of Formula (I) has a structure according to Formula (I-F),

[0225]

[0226] or a pharmaceutically acceptable salt thereof, wherein each of R3and m is independently according to any embodiment, or combination of embodiments described herein. In embodiments, m is 0 or 1.

[0227] In embodiments, a compound of Formula (I) has a structure according to Formula (I-G),

[0228]

[0229] or a pharmaceutically acceptable salt thereof, wherein each of R3and m is independently according to any embodiment, or combination of embodiments described herein. In embodiments, m is 0 or 1.

[0230] In embodiments, the substituents on the cyclohexyl moiety are cis to each other. In embodiments, the substituents on the cyclohexyl moiety are trans to each other. In embodiments, substituents on adjacent carbons of a cyclohexyl ring are cis to each other, e.g., according to Formula (I-G’),

[0231]

[0232] or a pharmaceutically acceptable salt thereof, wherein each of R3and m is independently according to any embodiment, or combination of embodiments described herein. In embodiments, m is 0 or 1.

[0233] Attorney Docket No.: 778138: CST9-008PC

[0234] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are trans to each other, e.g., according to Formula (I-G”),

[0235]

[0236] or a pharmaceutically acceptable salt thereof, wherein each of R3and m is independently according to any embodiment, or combination of embodiments described herein. In embodiments, m is 0 or 1.

[0237] In preferred embodiments, residues R1, R2, R3, R4, Cy, m, n, and o of compounds of formulas (I -A) to (I-G) are those as disclosed for compounds of formula (I).

[0238] Formula (II)

[0239] In preferred embodiments, a compound of Formula (I) has a structure according to Formula (II),

[0240]

[0241] or a pharmaceutically acceptable salt thereof, wherein R4is according to any embodiment described herein. In embodiments, R4is C2-C6alkyl or benzyl. Preferably, R4is benzyl. In embodiments, the pharmaceutically acceptable salt is the sodium salt or disodium salt.

[0242] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are cis to each other. In embodiments, substituents on adjacent carbons of a cyclohexyl ring are trans to each other.

[0243] In embodiments, a compound of Formula (II), or any sub formulas thereof, comprises two cis-cyclohexyl groups. In embodiments, a compound of Formula (II), or any subformulas thereof, comprises two trans-cyclohexyl groups. In embodiments, a compound of Formula (II), or any subformulas thereof, comprises a trans-cyclohexyl and a cis-cyclohexyl.

[0244] Attorney Docket No.: 778138: CST9-008PC

[0245] In embodiments, a compound of Formula (II) has a structure according to Formula (II-A),

[0246]

[0247] or a pharmaceutically acceptable salt thereof, wherein R4is according to any embodiment described herein. In embodiments, R4is C2-C6alkyl or benzyl.

[0248] In embodiments, a compound of Formula (II) has a structure according to Formula (II-B),

[0249]

[0250] or a pharmaceutically acceptable salt thereof, wherein R4is according to any embodiment described herein. In embodiments, R4is C2-C6alkyl or benzyl.

[0251] In embodiments, a compound of Formula (II) has a structure according to Formula (II-C),

[0252]

[0253] or a pharmaceutically acceptable salt thereof, wherein R4is according to any embodiment described herein. In embodiments, R4is C2-C6alkyl or benzyl.

[0254] Attorney Docket No.: 778138: CST9-008PC

[0255] Formula (III)

[0256] In embodiments, a compound of Formula (I) has a structure according to Formula (III),

[0257]

[0258] or a pharmaceutically acceptable salt thereof, wherein R3and p are each according to any embodiment described herein. In embodiments, R3is C1-C6alkyl, and p is 0 or 1.

[0259] In embodiments, a compound of Formula (III), or any subformulas thereof, comprises a cis-cyclohexyl group. In embodiments, a compound of Formula (III), or any subformulas thereof, comprises a trans-cyclohexyl group. In embodiments, substituents on adjacent carbons of a cyclohexyl ring are cis to each other, e.g., a structure according to Formula (III-A),

[0260]

[0261] or a pharmaceutically acceptable salt thereof, wherein R3and p are each according to any embodiment described herein. In embodiments, R3is C1-C6alkyl, and p is 0 or 1.

[0262] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are trans to each other, e.g., a structure according to Formula (III-B),

[0263]

[0264] or a pharmaceutically acceptable salt thereof, wherein R3and p are each according to any embodiment described herein. In embodiments, R3is C1-C6alkyl, and p is 0 or 1.

[0265] Attorney Docket No.: 778138: CST9-008PC

[0266] Formula (IV)

[0267] In embodiments, a compound of Formula (I) has a structure according to Formula (IV),

[0268]

[0269] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3, R4, X2, X3, and n are each according to any embodiment described herein. In embodiments, R1is H or Ci-Ce alkyl, R3is H or Ci-Ce alkyl optionally substituted by phenyl, R4is Ci-Ce alkyl or benzyl, each of X2and X3is independently N or CH, and n is 0 or 1.

[0270] In embodiments, a compound of Formula (IV), or any sub formulas thereof, comprises a cis-cyclohexyl group. In embodiments, a compound of Formula (IV), or any subformulas thereof, comprises a trans-cyclohexyl group. In embodiments, a compound of Formula (IV) has a structure according to Formula (IV-A),

[0271]

[0272] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3, R4, X2, X3, and n are each according to any embodiment described herein. In embodiments, R1is H or C1-C6alkyl, R3is H or C1-C6alkyl optionally substituted by phenyl, R4is C1-C6alkyl or benzyl, each of X2and X3is independently N or CH, and n is 0 or 1. In embodiments, a compound of Formula (IV) has a structure according to Formula (IV-B),

[0273]

[0274] Attorney Docket No.: 778138: CST9-008PC or a pharmaceutically acceptable salt thereof, wherein each of R1, R3, R4, X2, X3, and n are each according to any embodiment described herein. In embodiments, R1is H or Ci-Ce alkyl, R3is H or Ci-Ce alkyl optionally substituted by phenyl, R4is Ci-Ce alkyl or benzyl, each of X2and X3is independently N or CH, and n is 0 or 1.

[0275] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are cis to each other, e.g., a structure according to Formula (IV-B’),

[0276]

[0277] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3, R4, X2, X3, and n are each according to any embodiment described herein. In embodiments, R1is H or Ci-Ce alkyl, R3is H or Ci-Ce alkyl optionally substituted by phenyl, R4is Ci-Ce alkyl or benzyl, each of X2and X3is independently N or CH, and n is 0 or 1.

[0278] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are trans to each other, e.g., a structure according to Formula (IV-B”),

[0279]

[0280] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3, R4, X2, X3, and n are each according to any embodiment described herein. In embodiments, R1is H or C1-C6alkyl, R3is H or C1-C6alkyl optionally substituted by phenyl, R4is C1-C6alkyl or benzyl, each of X2and X3is independently N or CH, and n is 0 or 1. Formula (V)

[0281] In embodiments, a compound of Formula (I) has a structure according to Formula (V),

[0282] Attorney Docket No.: 778138: CST9-008PC

[0283]

[0284] or a pharmaceutically acceptable salt thereof, wherein R4is according to any embodiment described herein. In embodiments, R4is C1-C6alkyl or benzyl. In embodiments, R4is C1-C6alkyl. In embodiments, R4is unsubstituted C1-C6alkyl. In embodiments, R4is substituted C1-C6alkyl. In embodiments, R4is benzyl.

[0285] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are cis to each other. In embodiments, substituents on adjacent carbons of a cyclohexyl ring are trans to each other. In embodiments, the substituents on each cyclohexyl moiety are cis to each other. In embodiments, the substituents on each cyclohexyl moiety are trans to each other. In embodiments, the substituents on one cyclohexyl moiety are trans to each other, and the substituents on the other cyclohexyl moiety are cis to each other.

[0286] In embodiments, a compound of Formula (II) has a structure according to Formula (V-A),

[0287]

[0288] or a pharmaceutically acceptable salt thereof, wherein R4is according to any embodiment described herein. In embodiments, R4is C1-C6alkyl or benzyl.

[0289] Attorney Docket No.: 778138: CST9-008PC

[0290] In embodiments, a compound of Formula (V) has a structure according to

[0291] Formula (V-B),

[0292]

[0293] or a pharmaceutically acceptable salt thereof, wherein R4is according to any embodiment described herein. In embodiments, R4is Ci-Ce alkyl or benzyl.

[0294] In embodiments, a compound of Formula (V) has a structure according to

[0295] Formula (V-C),

[0296]

[0297] or a pharmaceutically acceptable salt thereof, wherein R4is according to any embodiment described herein. In embodiments, R4is Ci-Ce alkyl or benzyl.

[0298] Formula (VI)

[0299] In embodiments, a compound of Formula (I) has a structure according to Formula (VI),

[0300]

[0301] or a pharmaceutically acceptable salt thereof, wherein p is according to any embodiment described herein. In embodiments, p is 0. In embodiments, p is 1.

[0302] Attorney Docket No.: 778138: CST9-008PC

[0303] In embodiments, a compound of Formula (VI), or any subformulas thereof, comprises a cis-cyclohexyl group. In embodiments, a compound of Formula (VI), or any subformulas thereof, comprises a trans-cyclohexyl group.

[0304] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are cis to each other, e.g., a structure according to Formula (VI-A),

[0305]

[0306] or a pharmaceutically acceptable salt thereof, wherein p is according to any embodiment described herein. In embodiments, p is 0. In embodiments, p is 1.

[0307] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are trans to each other, e.g., a structure according to Formula (VI-B),

[0308]

[0309] or a pharmaceutically acceptable salt thereof, wherein p is according to any embodiment described herein. In embodiments, p is 0. In embodiments, p is 1.

[0310] Formula (VII)

[0311] In embodiments, a compound of Formula (I) has a structure according to Formula (VII),

[0312]

[0313] or a pharmaceutically acceptable salt thereof, wherein p is according to any embodiment described herein. In embodiments, p is 0. In embodiments, p is 1.

[0314] Attorney Docket No.: 778138: CST9-008PC

[0315] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are cis to each other, e.g., a structure according to Formula (VII-A),

[0316]

[0317] or a pharmaceutically acceptable salt thereof, wherein p is according to any embodiment described herein. In embodiments, p is 0. In embodiments, p is 1.

[0318] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are trans to each other, e.g., a structure according to Formula (VII-B),

[0319]

[0320] or a pharmaceutically acceptable salt thereof, wherein p is according to any embodiment described herein. In embodiments, p is 0. In embodiments, p is 1.

[0321] Formula (VIII)

[0322] In embodiments, a compound of Formula (I) has a structure according to Formula

[0323] (VIII),

[0324]

[0325] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3and R7Bare each according to any embodiment described herein. In embodiments, R1is H or Ci-Ce alkyl, R3is H or Ci-Ce alkyl optionally substituted by phenyl, and R7Bis H or Ci-Ce alkyl.

[0326] In embodiments, a compound of Formula (VIII), or any subformulas thereof, comprises a cis-cyclohexyl group. In embodiments, a compound of Formula (VIII), or any subformulas thereof, comprises a trans-cyclohexyl group.

[0327] Attorney Docket No.: 778138: CST9-008PC

[0328] In embodiments, a compound of Formula (I) has a structure according to Formula (VIII-A),

[0329]

[0330] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3and R7Bare each according to any embodiment described herein. In embodiments, R1is H or C1-C6alkyl, R3is H or C1-C6alkyl optionally substituted by phenyl, and R7Bis H or C1-C6alkyl. In embodiments, a compound of Formula (I) has a structure according to Formula (VIII-B),

[0331]

[0332] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3and R7Bare each according to any embodiment described herein. In embodiments, R1is H or Ci-Ce alkyl, R3is H or Ci-Ce alkyl optionally substituted by phenyl, and R7Bis H or Ci-Ce alkyl.

[0333] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are cis to each other, e.g., a structure according to Formula (VIII-B’),

[0334]

[0335] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3and R7Bare each according to any embodiment described herein. In embodiments, R1is H or Ci-Ce alkyl, R3is H or Ci-Ce alkyl optionally substituted by phenyl, and R7Bis H or Ci-Ce alkyl.

[0336] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are trans to each other, e.g., a structure according to Formula (VIII-B”),

[0337] Attorney Docket No.: 778138: CST9-008PC

[0338]

[0339] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3and R7Bare each according to any embodiment described herein. In embodiments, R1is H or Ci-Ce alkyl, R3is H or Ci-Ce alkyl optionally substituted by phenyl, and R7Bis H or Ci-Ce alkyl.

[0340] Formula (IX)

[0341] In embodiments, a compound of Formula (I) has a structure according to Formula (IX),

[0342]

[0343] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3and p are each according to any embodiment described herein. In embodiments, R1is H or Ci-Ce alkyl, R3is C2-C6 alkyl optionally substituted by phenyl, and p is 0 or 1. In embodiments, R1is H, R3C2-C6 alkyl optionally substituted by phenyl, and p is 1.

[0344] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are cis to each other. In embodiments, substituents on adjacent carbons of a cyclohexyl ring are trans to each other.

[0345] In embodiments, a compound of Formula (IX), or any sub formulas thereof, comprises two cz'.s-cyclohcxyl groups. In embodiments, a compound of Formula (IX), or any subformulas thereof, comprises two Zra / z.s-cyclohcxyl groups. In embodiments, a compound of Formula (IX), or any subformulas thereof, comprises a tra / z.s-cyclohcxyl and a cz'.s-cyclohcxyl.

[0346] In embodiments, a compound of Formula (I) has a structure according to Formula (IX-A),

[0347] Attorney Docket No.: 778138: CST9-008PC

[0348]

[0349] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3and p are each according to any embodiment described herein. In embodiments, R1is H or Ci-Ce alkyl, R3is C2-C6 alkyl optionally substituted by phenyl, and p is 0 or 1. In embodiments, R1is H, R3C2-C6 alkyl optionally substituted by phenyl, and p is 1.

[0350] In embodiments, a compound of Formula (I) has a structure according to Formula (IX-B),

[0351]

[0352] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3and p are each according to any embodiment described herein. In embodiments, R1is H or Ci-Ce alkyl, R3is C2-C6 alkyl optionally substituted by phenyl, and p is 0 or 1. In embodiments, R1is H, R3C2-C6 alkyl optionally substituted by phenyl, and p is 1.

[0353] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are cis to each other, e.g., a structure according to Formula (IX-B’),

[0354]

[0355] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3and R7Bare each according to any embodiment described herein. In embodiments, R1is H or Ci-Ce alkyl, R3is C2-C6 alkyl optionally substituted by phenyl, and R7Bis H or Ci-Ce alkyl.

[0356] In embodiments, substituents on adjacent carbons of a cyclohexyl ring are cis to each other, e.g., a structure according to Formula (IX-B”),

[0357] Attorney Docket No.: 778138: CST9-008PC

[0358]

[0359] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3and R7Bare each according to any embodiment described herein. In embodiments, R1is H or Ci-Ce alkyl, R3is C2-C6 alkyl optionally substituted by phenyl, and R7Bis H or Ci-Ce alkyl.

[0360] In embodiments, a compound of Formula (I) has a structure according to Formula (IX-C),

[0361]

[0362] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3and p are each according to any embodiment described herein. In embodiments, R1is H or Ci-Ce alkyl, R3is C2-C6 alkyl optionally substituted by phenyl, and p is 0 or 1. In embodiments, R1is H, R3is C2-C6 alkyl optionally substituted by phenyl, and p is 1.

[0363] In embodiments, a compound of Formula (I) has a structure according to Formula (IX-C’),

[0364]

[0365] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3and p are each according to any embodiment described herein. In embodiments, R1is H or Ci-Ce alkyl, R3is C2-C6 alkyl optionally substituted by phenyl, and p is 0 or 1. In embodiments, R1is H, R3is C2-C6 alkyl optionally substituted by phenyl, and p is 1.

[0366] In embodiments, a compound of Formula (I) has a structure according to Formula (IX-C”),

[0367] Attorney Docket No.: 778138: CST9-008PC

[0368]

[0369] or a pharmaceutically acceptable salt thereof, wherein each of R1, R3and p are each according to any embodiment described herein. In embodiments, R1is H or Ci-Ce alkyl, R3is C2-C6 alkyl optionally substituted by phenyl, and p is 0 or 1. In embodiments, R1is H, R3is C2-C6 alkyl optionally substituted by phenyl, and p is 1.

[0370] Formula (X)

[0371] In another aspect, the compound used according to the present invention is a compound having a structure according to Formula (X),

[0372]

[0373] or a pharmaceutically acceptable salt thereof, wherein Cy is independently C5-C10 cycloalkyl, 5- to 7-membered heterocyclyl, 5- to 6-membered heteroaryl or phenyl.

[0374] In embodiments, the compound used according to the present invention is a compound having a structure according to Formula (X),

[0375]

[0376] or a pharmaceutically acceptable salt thereof, wherein Cy is independently C5-C7 cycloalkyl, 5- to 7-membered heterocyclyl, 5- to 6-membered heteroaryl or phenyl.

[0377] In embodiments, non-hydrogen groups on different carbons of the cyclohexyl moiety substituted by -CO2H in Formula (X) are cis to each other (also referred to as a “czs-cyclohexyl”). In embodiments, non-hydrogen groups on different carbons of the cyclohexyl moiety substituted by -CO2H in Formula (X) are trans to each other (also referred to as a ‘7ra / ?.s-cyclohcxyl”).

[0378] In embodiments where Cy is C5-C10 cycloalkyl (e.g., a cyclohexyl, a cyclopentyl, or a decahydronaphthalenyl) or 5- to 7-membered heterocyclyl, non-hydrogen groups on different carbons of on a Cy moiety are cis to each other (also referred to as a “czs-Cy”).

[0379] Attorney Docket No.: 778138: CST9-008PC

[0380] In embodiments where Cy is C5-C7 cycloalkyl (e.g., a cyclohexyl or a cyclopentyl) or 5-to 7-membered heterocyclyl, non-hydrogen groups on different carbons of on a Cy moiety are cis to each other (also referred to as a “czs-Cy”). In embodiments where Cy is C5-C10 cycloalkyl (e.g., a cyclohexyl, a cyclopentyl, or a decahydronaphthalenyl) or 5- to 7-membered heterocyclyl, non-hydrogen groups on different carbons of a Cy moiety are trans to each other (also referred to as a “trazzs-Cy”). In embodiments where Cy is C5-C7 cycloalkyl (e.g., a cyclohexyl or a cyclopentyl) or 5- to 7-membered heterocyclyl, nonhydrogen groups on different carbons of a Cy moiety are trans to each other (also referred to as a “trazzs-Cy”).

[0381] In embodiments, a compound of Formula (X), or any subformulas thereof, comprises a cz.s-cyclohcxyl and a cis-Cy (e.g., a cz.s-cyclohcxyl, a cz.s-cyclopcntyl, or a cz'.s-dccahydronaphthalcnyl). In embodiments, a compound of Formula (X), or any subformulas thereof, comprises a cz.s-cyclohcxyl and a cis-Cy (e.g., a cz.s-cyclohcxyl or a cz.s-cyclopcntyl).

[0382] In embodiments, a compound of Formula (X), or any subformulas thereof, comprises a Zrazz.s-cyclohcxyl and a trans-Cy (e.g., a Zrazz.s-cyclohcxyl, a Zrazz.s-cyclopcntyl, or a trans-decahydronaphthalenyl). In embodiments, a compound of Formula (X), or any subformulas thereof, comprises a Zrazz.s-cyclohcxyl and a trans-Cy (e.g., a trans-cyclohexyl or a Zrazz.s-cyclopcntyl). In embodiments, a compound of Formula (X), or any subformulas thereof, comprises a Zrazz.s-cyclohcxyl and a cis-Cy (e.g., a cz.s-cyclohcxyl, a cz.s-cyclopcntyl, or a cz'.s-dccahydronaphthalcnyl). In embodiments, a compound of Formula (X), or any subformulas thereof, comprises a Zrazz.s-cyclohcxyl and a cis-Cy (e.g., a cz.s-cyclohcxyl or a cz.s-cyclopcntyl). In embodiments, a compound of Formula (X), or any subformulas thereof, comprises a cz.s-cyclohcxyl and a trans-Cy (e.g., a trans-cyclohexyl, a Zrazz.s-cyclopcntyl, or a tzYzzz.s-dccahydronaphthalcnyl). In embodiments, a compound of Formula (X), or any subformulas thereof, comprises a cz.s-cyclohcxyl and a trans-Cy (e.g., a Zrazz.s-cyclohcxyl or a trazzs-cyclopentyl).

[0383] In another aspect, the compound used according to the present invention is a compound having a structure according to Formula (X-A),

[0384]

[0385] Attorney Docket No.: 778138: CST9-008PC or a pharmaceutically acceptable salt thereof, wherein Cy is independently C5-C10 cycloalkyl, 5- to 7-membered heterocyclyl, 5- to 6-membered heteroaryl or phenyl.

[0386] In another aspect, the compound used according to the present invention is a compound having a structure according to Formula (X-A),

[0387]

[0388] or a pharmaceutically acceptable salt thereof, wherein Cy is independently C5-C7 cycloalkyl, 5- to 7-membered heterocyclyl, 5- to 6-membered heteroaryl or phenyl.

[0389] In another aspect, the compound used according to the present invention is a compound having a structure according to Formula (X-B),

[0390]

[0391] or a pharmaceutically acceptable salt thereof, wherein Cy is independently C5-C10 cycloalkyl, 5- to 7-membered heterocyclyl, 5- to 6-membered heteroaryl or phenyl.

[0392] In another aspect, the compound used according to the present invention is a compound having a structure according to Formula (X-B),

[0393]

[0394] or a pharmaceutically acceptable salt thereof, wherein Cy is independently C5-C7 cycloalkyl, 5- to 7-membered heterocyclyl, 5- to 6-membered heteroaryl or phenyl.

[0395] Similarly, the invention also features pharmaceutically acceptable salts of compounds described herein, including pharmaceutically acceptable salts (e.g., sodium salts) of any Compound described. In embodiments, a pharmaceutically acceptable salt is a mono-sodium salt (e.g., of a mono-acid or a di-acid described herein). In embodiments, a pharmaceutically acceptable salt is a di-sodium salt (e.g., of a di-acid described herein).

[0396] Attorney Docket No.: 778138: CST9-008PC

[0397] Exemplary Compounds

[0398] Exemplary compounds include those described throughout the present disclosure, as well as any pharmaceutically acceptable form thereof (e.g., a pharmaceutically acceptable salt thereof), including certain specifically-described compounds.

[0399] For example, non-limiting compounds of the invention include those of Table 1, as well as any pharmaceutically acceptable form thereof (e.g., a pharmaceutically acceptable salt thereof). Compounds of the invention include diastereomers of illustrative structures unless otherwise noted. Exemplary diastereomers of certain of Compounds (1)-(36) are also provided in Table 1. Similarly, the invention also features pharmaceutically acceptable salts of compounds described herein, including pharmaceutically acceptable salts (e.g., sodium salts) of any Compound described in Table 1.

[0400] Additionally, if stereochemistry is not indicated, it is understood that the formula encompasses all permitted stereoisomers (e.g., enantiomers and diastereomers). As described elsewhere herein, non-hydrogen substituents on different carbon atoms of a ring (e.g., a cyclohexyl, a cyclopentyl, or a decahydronaphthalenyl) are understood to be cis- or trans- relative to each other, with certain non-limiting embodiments also identified in Table 1.

[0401] Table 1

[0402]

[0403] Attorney Docket No.: 778138: CST9-008PC

[0404]

[0405] Attorney Docket No.: 778138: CST9-008PC

[0406]

[0407] Attorney Docket No.: 778138: CST9-008PC

[0408]

[0409] Attorney Docket No.: 778138: CST9-008PC

[0410]

[0411] Attorney Docket No.: 778138: CST9-008PC

[0412]

[0413] Attorney Docket No.: 778138: CST9-008PC

[0414]

[0415] In embodiments, a compound is Compound (1) (e.g., Compound czA-(l)), or a pharmaceutically acceptable salt thereof. In embodiments, a compound is Compound (1) (e.g., Compound czA-(l)). In embodiments, a compound is a pharmaceutically acceptable salt of Compound (1) (e.g., a sodium salt of Compound (1) such as a monosodium or a disodium salt of Compound (1)). In embodiments, a compound is a pharmaceutically acceptable salt of Compound czA-(l) (e.g., a sodium salt of Compound cis- (1) such as a monosodium or a disodium salt of Compound czs-(l)).

[0416] Definitions

[0417] Pharmaceutically acceptable: The term “pharmaceutically acceptable,” as used herein, refers to substances that, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. Accordingly, pharmaceutically acceptable relates toAttorney Docket No.: 778138: CST9-008PC substances that are not biologically or otherwise undesirable, i.e., the material can be administered to an individual along with the relevant active compound without causing clinically unacceptable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.

[0418] Pharmaceutically acceptable form: Unless otherwise indicated herein, any description of a formula or compound also includes any pharmaceutically acceptable forms of the compound. As used herein, a “pharmaceutically acceptable form” of a disclosed formula or compound includes, but is not limited to, pharmaceutically acceptable salts, hydrates, solvates, isomers, polymorphs, prodrugs, and isotopically labeled derivatives of disclosed formulas and compounds. In embodiments, a “pharmaceutically acceptable form” includes, but is not limited to, pharmaceutically acceptable salts, isomers, prodrugs and isotopically labeled derivatives of disclosed compounds. In embodiments, a “pharmaceutically acceptable form” includes, but is not limited to, pharmaceutically acceptable salts, stereoisomers, prodrugs and isotopically labeled derivatives of disclosed compounds. In certain embodiments, the pharmaceutically acceptable form is a pharmaceutically acceptable salt of a disclosed formula or compound as described herein.

[0419] Pharmaceutically acceptable salt: Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66:1-19. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,Attorney Docket No.: 778138: CST9-008PC persulfate, 3 -phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1–4-alkyl)4salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, sulfonate, and aryl sulfonate. Further pharmaceutically acceptable salts include salts formed from the quartemization of an amine using an appropriate electrophile, e.g., an alkyl halide, to form a quartemized alkylated amino salt.

[0420] Prodrug: Pharmaceutically acceptable forms of any compound described herein can include prodrugs. As used herein, the term “prodrug” refers to compounds that are transformed in vivo to yield a disclosed compound or any other pharmaceutically acceptable form of the compound. In embodiments, a prodrug may be inactive when administered to a subject but may be converted in vivo to an active compound, for example, by hydrolysis. See, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam). A discussion of prodrugs is provided in Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” A. C. S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987. Prodrugs can typically be prepared using well known methods, such as those described in Burger's Medicinal Chemistry and Drug Discovery, 172-178, 949-982 (Manfred E. Wolff ed., 5th ed., 1995), and Design of Prodrugs (H. Bundgaard ed., Elselvier, New York, 1985). The term “prodrug” is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a subject. Prodrugs of compounds described herein may be prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to provide a compound described herein (i.e., the parent active compound). Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate andAttorney Docket No.: 778138: CST9-008PC benzoate derivatives of an alcohol or acetamide, formamide and benzamide derivatives of an amine functional group in the active compound and the like. Other examples of prodrugs include compounds that comprise — NO, — NO2, — ONO, or — ONO2 moieties.

[0421] The variable groups defined herein, e.g., alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, aryloxy, aryl, heterocycle and heteroaryl groups defined herein, whether used alone or as part of another group, can be optionally substituted unless otherwise indicated. In embodiments, a variable group is unsubstituted. In embodiments, a variable group is substituted (e.g., comprising 1, 2, 3, 4, or 5 substituents (e.g., as described herein) and as valency and stability permits). Still further embodiments are described herein.

[0422] “Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0423] Aliphatic: As used herein, the term aliphatic refers to hydrocarbons and includes both saturated and unsaturated hydrocarbons. An aliphatic may be linear, branched, or cyclic. For example, C1-C20 aliphatics can include C1-C20 alkyls (e.g., linear or branched C1-C20 saturated alkyls), C2-C20 alkenyls (e.g., linear or branched C4-C20 dienyls, linear, or branched C6-C20 trienyls, and the like), and C2-C20 alkynyls (e.g., linear or branched C2-C20 alkynyls). C1-C20 aliphatics can include C3-C20 cyclic aliphatics (e.g., C3-C20 cycloalkyls, C4-C20 cycloalkenyls, or C8-C20 cycloalkynyls). In certain embodiments, the aliphatic may comprise one or more cyclic aliphatic and / or one or more heteroatoms such as oxygen, nitrogen, or sulfur and may optionally be substituted with one or more substituents such as alkyl, halo, alkoxyl, hydroxy, amino, aryl, ether, ester or amide. An aliphatic group is unsubstituted or substituted with one or more substituent groups as described herein. For example, an aliphatic may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO2H, -CO2R’, -CN, -OH, -OR’, -OCOR’, -OCO2R’, -NH2, -NHR’, -N(R’)2, -SR’ or-SO2R’, wherein each instance of R’ independently is C1-C20 aliphatic (e.g., Ci-C20 alkyl, C1-C15 alkyl, C1-C10 alkyl, or C1-C3 alkyl). In embodiments, R’ independently is an unsubstituted alkyl (e.g., unsubstituted C1-C20 alkyl, C1-C15 alkyl, C1-C10 alkyl, or C1-C3 alkyl). In embodiments, R’ independently is unsubstituted C1-C3 alkyl. In embodiments, the aliphatic is unsubstituted. In embodiments, the aliphatic does not include any heteroatoms.

[0424] Attorney Docket No.: 778138: CST9-008PC

[0425] Alkyl: As used herein, the term “alkyl” means acyclic linear and branched hydrocarbon groups, e.g., “C1-C20 alkyl” refers to alkyl groups having 1-20 carbons and “C1-C4 alkyl” refers to alkyl groups having 1-4 carbons. Alkyl groups include C1-C20 alkyl, C1-C15 alkyl, C1-C10 alkyl, C1-C4 alkyl, and C1-C3 alkyl). In embodiments, an alkyl group is C1-C4 alkyl. An alkyl group may be linear or branched. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl tert-pentylhexyl, isohexyl, etc. The term “lower alkyl" means an alkyl group straight chain or branched alkyl having 1 to 6 carbon atoms. Other alkyl groups will be readily apparent to those of skill in the art given the benefit of the present disclosure. An alkyl group may be unsubstituted or substituted with one or more substituent groups as described herein. For example, an alkyl group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO2H, -CO2R’, -CN, -OH, -OR’, -OCOR’, -OCO2R’, -NH2, -NHR’, -N(R’)2, -SR’ or-SO2R’, wherein each instance of R’ independently is C1-C20 aliphatic (e.g., C1-C20 alkyl, C1-C15 alkyl, C1-C10 alkyl, C1-C4 alkyl, or C1-C3 alkyl). In embodiments, R’ independently is an unsubstituted alkyl (e.g., unsubstituted C1-C20 alkyl, C1-C15 alkyl, C1-C10 alkyl, or C1-C3 alkyl). In embodiments, R’ independently is unsubstituted C1-C3 alkyl. Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, zso-propyl, n-butyl,.sec-butyl, zso-butyl, tert-butyl, and the like. In embodiments, the alkyl is substituted (e.g., with 1, 2, 3, 4, 5, or 6 substituent groups as described herein). In embodiments, an alkyl group is substituted with a-OH group and may also be referred to herein as a “hydroxyalkyl” group, where the prefix denotes the -OH group and “alkyl” is as described herein. In embodiments, an alkyl group is substituted with a-OR’ group. Non-limiting examples of substituted alkyl groups include hydroxymethyl, chloromethyl, trifluoromethyl, aminomethyl, 1 -chloroethyl, 2-hydroxyethyl, 1,2-difluoroethyl, 3 -carboxypropyl, and the like. In substituent groups with multiple alkyl groups such as (Ci-Ce alkyl)2amino, the alkyl groups may be the same or different.

[0426] Alkylene: The term “alkylene,” as used herein, represents a saturated divalent straight or branched chain hydrocarbon group and is exemplified by methylene, ethylene, isopropylene and the like. Likewise, the term “alkenylene” as used herein represents an unsaturated divalent straight or branched chain hydrocarbon group having one or more unsaturated carbon-carbon double bonds that may occur in any stable point along theAttorney Docket No.: 778138: CST9-008PC chain, and the term “alkynylene” herein represents an unsaturated divalent straight or branched chain hydrocarbon group having one or more unsaturated carbon-carbon triple bonds that may occur in any stable point along the chain. In certain embodiments, an alkylene, alkenylene, or alkynylene group may comprise one or more cyclic aliphatic and / or one or more heteroatoms such as oxygen, nitrogen, or sulfur and may optionally be substituted with one or more substituents such as alkyl, halo, alkoxyl, hydroxy, amino, aryl, ether, ester or amide. For example, an alkylene, alkenylene, or alkynylene may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO2H, -CO2R’, -CN, -OH, -OR’, -OCOR’, -OCO2R’, -NH2, -NHR’, -N(R’)2, -SR’ or -SO2R’, wherein each instance of R’ independently is C1–C20aliphatic (e.g., C1–C20alkyl, C1-C15 alkyl, C1-C10 alkyl, or C1-C3 alkyl). In embodiments, R’ independently is an unsubstituted alkyl (e.g., unsubstituted C1–C20alkyl, C1-C15 alkyl, C1-C10 alkyl, or C1-C3 alkyl). In embodiments, R’ independently is unsubstituted C1–C3alkyl. In certain embodiments, an alkylene, alkenylene, or alkynylene is unsubstituted. In certain embodiments, an alkylene, alkenylene, or alkynylene does not include any heteroatoms.

[0427] Alkenyl: As used herein, “alkenyl” means any linear or branched hydrocarbon chains having one or more unsaturated carbon-carbon double bonds that may occur in any stable point along the chain, e.g., “C2–C20alkenyl” refers to an alkenyl group having 2-20 carbons. For example, an alkenyl group includes prop-2-enyl, but-2-enyl, but-3-enyl, 2-methylprop-2-enyl, hex-2-enyl, hex-5-enyl, 2,3-dimethylbut-2-enyl, and the like. In embodiments, the alkenyl comprises 1, 2, or 3 carbon-carbon double bond. In embodiments, the alkenyl comprises a single carbon-carbon double bond. In embodiments, multiple double bonds (e.g., 2 or 3) are conjugated. An alkenyl group may be unsubstituted or substituted with one or more substituent groups as described herein. For example, an alkenyl group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO2H, -CO2R’, -CN, -OH, -OR’, -OCOR’, -OCO2R’, -NH2, -NHR’, -N(R’)2, -SR’ or-SO2R’, wherein each instance of R’ independently is C1–C20aliphatic (e.g., C1–C20alkyl, C1-C15 alkyl, C1-C10 alkyl, or C1-C3 alkyl). In embodiments, R’ independently is an unsubstituted alkyl (e.g., unsubstituted C1–C20alkyl, C1-C15 alkyl, C1-C10 alkyl, or C1-C3 alkyl). In embodiments, R’ independently is unsubstituted C1-C3 alkyl. In embodiments, the alkenyl is unsubstituted. In embodiments, the alkenyl is substituted (e.g., with 1, 2, 3, 4, 5, or 6Attorney Docket No.: 778138: CST9-008PC substituent groups as described herein). In embodiments, an alkenyl group is substituted with a-OH group and may also be referred to herein as a “hydroxyalkenyl” group, where the prefix denotes the -OH group and “alkenyl” is as described herein. Nonlimiting examples of alkenyl groups include ethenyl, 3-propenyl, 1 -propenyl (also 2-methylethenyl), isopropenyl (also 2-methylethen-2-yl), buten-4-yl, and the like. Nonlimiting examples of substituted alkenyl groups include 2-chloroethenyl (also 2-chlorovinyl), 4-hydroxybuten-l-yl, 7-hydroxy-7-methyloct-4-en-2-yl, 7-hydroxy-7-methyloct-3,5-dien-2-yl, and the like.

[0428] Alkynyl: As used herein, “alkynyl” means any hydrocarbon chain of either linear or branched configuration, having one or more carbon-carbon triple bonds occurring in any stable point along the chain, e.g., “C2-C20 alkynyl” refers to an alkynyl group having 2-20 carbons. Examples of an alkynyl group include prop-2 -ynyl, but-2-ynyl, but-3-ynyl, pent-2-ynyl, 3-methylpent-4-ynyl, hex-2-ynyl, hex-5-ynyl, etc. In embodiments, an alkynyl comprises one carbon-carbon triple bond. An alkynyl group may be unsubstituted or substituted with one or more substituent groups as described herein. For example, an alkynyl group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO2H, -CO2R’, -CN, -OH, -OR’, -OCOR’, -OCO2R’, -NH2, -NHR’, -N(R’)2, -SR’ or-SO2R’, wherein each instance of R’ independently is C1-C20 aliphatic (e.g., C1-C20 alkyl, C1-C15 alkyl, C1-C10 alkyl, or C1–C3alkyl). In embodiments, R’ independently is an unsubstituted alkyl (e.g., unsubstituted C1-C20 alkyl, C1-C15 alkyl, C1-C10 alkyl, or C1-C3 alkyl). In embodiments, R’ independently is unsubstituted C1-C3 alkyl. In embodiments, the alkynyl is unsubstituted. In embodiments, the alkynyl is substituted (e.g., with 1, 2, 3, 4, 5, or 6 substituent groups as described herein). Nonlimiting examples of alkynyl groups include ethynyl, prop-2-ynyl (also propargyl), propyn-l-yl, and 2-methyl-hex-4-yn-l-yl. Nonlimiting examples of substituted alkynyl groups include, 5 -hydroxy-5 -methylhex-3-ynyl, 6-hydroxy-6-methylhept-3-yn-2-yl, 5 -hydroxy-5 -ethylhept-3 -ynyl, and the like.

[0429] Alkoxy: The term “alkoxy” refers to the group -O-alkyl, wherein the alkyl group is as defined above, including from 1 to 10 carbon atoms of a straight, branched, saturated cyclic configuration and combinations thereof, attached to the parent molecular structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy, cyclopropyloxy, cyclohexyloxy and the like. “Lower alkoxy” refers to alkoxy groups containing one to six carbons. In embodiments, C1-4 alkoxy is anAttorney Docket No.: 778138: CST9-008PC alkoxy group which encompasses both straight and branched chain alkyls of from 1 to 4 carbon atoms. Unless stated otherwise in the specification, an alkoxy group can be optionally substituted by one or more substituents (e.g., as described herein for alkyl). The terms “alkenoxy” and “alkynoxy” mirror the above description of “alkoxy” wherein the prefix “alk” is replaced with “alken” or “alkyn” respectively, and the parent “alkenyl" or “alkynyl” terms are as described herein.

[0430] Amide: The term “amide” or “amido” refers to a chemical moiety with formula C(0)N(R’)2, -C(O)N(R’)-, -NR’C(O)R’, or -NR’C(O)-, where each R’ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl (bonded through a chain carbon), cycloalkyl, aryl, arylalkyl, heteroaryl (bonded through a ring carbon), heteroarylalkyl, or heterocycloalkyl (bonded through a ring carbon), unless stated other-wise in the specification, each of which moiety can itself be optionally substituted as described herein, or two R’ can combine with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring.

[0431] Amino: The term “amino” or “amine” refers to a -N(R’)2 group, where each R’ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl (bonded through a chain carbon), cycloalkyl, aryl, arylalkyl, heteroaryl (bonded through a ring carbon), heteroarylalkyl, or heterocycloalkyl (bonded through a ring carbon), unless stated otherwise in the specification, each of which moiety can itself be optionally substituted as described herein, or two R’ can combine with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring. In embodiments, an amino group is -NHR’, where R’ is aryl (“arylamino”), heteroaryl (“heteroarylamino”), or alkyl (“alkylamino”).

[0432] Aryl: The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of six to fourteen ring members, wherein said ring system has a single point of attachment to the rest of the molecule, wherein at least one ring in the system is aromatic, and wherein each ring in the system contains 4 to 7 ring members. In embodiments, an aryl group has 6 ring carbon atoms (“Ce aryl,” e.g., phenyl). In embodiments, an aryl group has 10 ring carbon atoms (“Cio aryl,” e.g., naphthyl such as 1 -naphthyl and 2-naphthyl). In embodiments, an aryl group has 14 ring carbon atoms (“Ci4 aryl,” e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate theAttorney Docket No.: 778138: CST9-008PC number of carbon atoms in the aryl ring system. Aryl groups can be unsubstituted or substituted. Exemplary aryls include phenyl, naphthyl, and anthracene. Aryl rings can be, for example, phenyl or naphthyl ring each optionally substituted with one or more moieties capable of replacing one or more hydrogen atoms. Non-limiting examples of aryl groups include: phenyl, naphthylen-l-yl, naphthylen-2-yl, 4-fluorophenyl, 2-hydroxyphenyl, 3 -methylphenyl, 2-amino-4-fluorophenyl, 2-(N,N-diethylamino)phenyl, 2-cyanophenyl, 2,6-di-tert-butylphenyl, 3 -methoxyphenyl, 8-hydroxynaphthylen-2-yl 4,5-dimethoxynaphthylen-l-yl, and 6-cyano-naphthylen-l-yl. Aryl groups also include, for example, phenyl or naphthyl rings fused with one or more saturated or partially saturated carbon rings (e.g., bicyclo[4.2.0]octa-l, 3, 5-trienyl, indanyl), which can be substituted at one or more carbon atoms of the aromatic and / or saturated or partially saturated rings.

[0433] Arylalkyl'. The term “arylalkyl” refers to an -(alkylene)-aryl radical where aryl and alkylene are as disclosed herein and which are optionally substituted by one or more of the exemplary substituent groups described herein. The “arylalkyl” group is bonded to the parent molecular structure through the alkylene moiety. The term “arylalkoxy” refers to an -O- [arylalkyl] radical (-O-[(alkylene)-aryl]), which is attached to the parent molecular structure through the oxygen.. Examples of arylalkyl groups include, for example, benzyl, 1 -phenylethyl, 2-phenylethyl, 3 -phenylpropyl, 2-phenylpropyl, fluorenylmethyl and the like.

[0434] Arylene: The term “arylene” as used herein refers to an aryl group that is divalent (that is, having two points of attachment to the molecule). Exemplary arylenes include phenylene (e.g., unsubstituted phenylene or substituted phenylene).

[0435] Carbonyl'. The term “carbonyl” refers to a -C(=O)R’, or -C(=O)- group, where R is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl (bonded through a chain carbon), cycloalkyl, aryl, arylalkyl, amino, hydroxyl, heteroaryl (bonded through a ring carbon), heteroarylalkyl, heterocycloalkyl (bonded through a ring carbon), unless stated other- wise in the specification, each of which moiety can itself be optionally substituted as described herein.

[0436] Cyclic. The term “cyclic” as used herein, refers to any covalently closed structure. Cyclic moieties include, for example, carbocycles (e.g., aryls and cycloalkyls), heterocycles (e.g., heteroaryls and heterocycloalkyls), aromatics (e.g., aryls and heteroaryls), and non-aromatics (e.g., cycloalkyls and heterocycloalkyls). In

[0437] Attorney Docket No.: 778138: CST9-008PC embodiments, cyclic moieties are optionally substituted. In embodiments, cyclic moieties form part of a ring system.

[0438] Cycloaliphatic: The term “cycloaliphatic” refers to a monocyclic or polycyclic radical that contains only carbon and hydrogen and can be saturated or partially unsaturated. A cycloaliphatic group may be substituted or unsubstituted. Fully saturated cycloaliphatics can be termed “cycloalkyl”. Partially unsaturated cycloalkyl groups can be termed “cycloalkenyl” if the carbocycle contains at least one double bond, or "cycloalkynyl" if the carbocycle contains at least one triple bond. Cycloaliphatic groups include groups having from 3 to 13 ring atoms (e.g., C3-13 cycloalkyl). Whenever it appears herein, a numerical range such as “3 to 10” refers to each integer in the given range, e.g., “3 to 10 carbon atoms” means that the cycloaliphatic group (e.g., cycloalkyl) can consist of 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, etc., up to and including 10 carbon atoms. The term “cycloaliphatic” also includes bridged and spiro-fused cyclic structures containing no heteroatoms. The term also includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups. Polycyclic cycloaliphatic groups include bicycles, tricycles, tetracycles, and the like. In embodiments, “cycloalkyl” can be a C3-8 cycloalkyl group. In embodiments, “cycloalkyl” can be a C3-5 cycloalkyl group. Illustrative examples of cycloaliphatic groups include but are not limited to the following moieties: C3-6 cycloaliphatic groups include, without limitation, cyclopropyl (C3), cyclobutyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (Ce), cyclohexenyl (Ce), cyclohexadienyl (Ce) and the like. Examples of C3-7 cycloaliphatic groups include norbomyl (C7). Examples of C3-8 cycloaliphatic groups include the aforementioned C3-7 carbocyclyl groups as well as cycloheptyl (C7), cycloheptadienyl (C7), cyclohept-atrienyl (C7), cyclooctyl (Cs), bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, and the like. Examples of C3-13 cycloaliphatic groups include the aforementioned C3-8 carbocyclyl groups as well as octahydro- 1H indenyl, decahydronaphthalenyl, spiro[4.5]decanyl, and the like. Additional, nonlimiting examples of cycloaliphatic groups (including cycloalkyl groups) include: cyclopropyl, 2-methyl-cyclopropyl, cyclopropenyl, cyclobutyl, 2,3-dihydroxycyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctanyl, decalinyl, 2,5-dimethylcyclopentyl, 3,5-dichlorocyclohexyl, 4-hydroxycyclohexyl, 3,3,5-trimethylcyclohex-l-yl, octahydropentalenyl, octahydro- 1H-indenyl, 3a,4,5,6,7,7a-hexahydro-3H-inden-4-yl, decahydroazulenyl;

[0439] Attorney Docket No.: 778138: CST9-008PC bicyclo[6.2.0]decanyl, decahydronaphthalenyl, dodecahydro- 1H- fluorenyl, bicyclo-[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, 1,3-dimethyl[2.2.1]heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl. A “bicycloalkyl” group includes bridged cycloalkyl groups such as bicyclo [l.l.l]pentyl, bicyclo[2.1.1]heptane, adamantanyl, and norbornanyl; as well as spiro cycloalkyl groups include spiro[3.3]heptane and spiro[4.5]decane. A “heterobicycloalkyl” group is a bicycloalkyl comprising at least one heteroatom in the ring framework.

[0440] Ester. The term “ester” refers to a group of formula -C(O)OR’ or -R’OC(O)-, where R’ is selected from alkyl, alkenyl, alkynyl, heteroalkyl (bonded through a chain carbon), cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, or heterocycloalkyl as described herein.

[0441] Halogen'. As used herein, the term "halogen" shall mean chlorine, bromine, fluorine, and iodine.

[0442] Haloalkyl: The term “haloalkyl” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen. Haloalkyl groups include perhaloalkyl groups, wherein all hydrogens of an alkyl group have been replaced with halogens (e.g., -CF3, CF2CF3). Haloalkyl groups can optionally be substituted with one or more substituents in addition to halogen. Examples of haloalkyl groups include, but are not limited to, fluoromethyl, dichloroethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl groups.

[0443] Haloalkoxy: The term “haloalkoxy” refers to the group -O-haloalkyl, wherein the haloalkyl group is as defined above. Examples of haloalkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, and pentafluoroethoxyl.

[0444] Heteroalky. The term “heteroalkyl” is meant a branched or unbranched alkyl, alkenyl, or alkynyl group as defined herein (including groups having from 1 to 14 carbon atoms, preferably 1 to 10 carbon atoms) which also comprise at least one heteroatom (e.g., 1, 2, 3 or 4 heteroatoms, preferably 1 to 3 heteroatoms) independently selected from the group consisting of N, O, S, and P, preferably selected from the group consisting of N, O and S. For example, “1- to 6-membered heteroalkyl” can encompass heteroalkyl groups having 1-6 atoms (e.g., carbon atoms and at least one heteroatom selected from N, O, S, and P) along the main chain of the group. In embodiments, heteroalkyls excludeAttorney Docket No.: 778138: CST9-008PC peroxy (O-O) moieties. Heteroalkyls include tertiary amines, secondary amines, ethers, thioethers, amides, thioamides, carbamates, thiocarbamates, hydrazones, imines, phosphodiesters, phosphoramidates, sulfonamides, and disulfides. A heteroalkyl group may optionally include monocyclic, bicyclic, or tricyclic rings, in which each ring desirably has three to six members. Examples of heteroalkyls include polyethers, such as methoxymethyl and ethoxyethyl. Accordingly, the term “heteroalkoxy” refers to the group -O-heteroalkyl, where the group is attached to the parent molecular structure via the oxygen.

[0445] Heteroalkylene'. The term “heteroalkylene” as used herein, represents a divalent form of a heteroalkyl group as described herein.

[0446] Heteroaryl: The term “heteroaryl,” as used herein, is defined herein as one or more rings having from 5 to 20 atoms, preferably 5 to 10 atoms, wherein at least one atom, preferably 1 to 3 atoms, in at least one ring is a heteroatom chosen from nitrogen (N), oxygen (O), or sulfur (S), and wherein further at least one of the rings that includes a heteroatom is aromatic, and with the proviso that the ring of said group does not contain two adjacent O or S atoms. In embodiments, “heteroaryl” refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of six to fourteen ring members, preferably 6 to 10 ring members, wherein said ring system has a single point of attachment to the rest of the molecule, wherein at least one ring in the system is aromatic, wherein each ring in the system contains 4 to 7 ring members, and wherein at least one ring atom, preferably 1 to 3 ring atoms, is a heteroatom such as, but not limited to, nitrogen, oxygen, or sulfur. In heteroaryl groups that include 2 or more fused rings, the non-heteroatom bearing ring may be a carbocycle (e.g., 6,7-Dihydro-5H-cyclopentapyrimidine) or aryl (e.g., benzofuranyl, benzothiophenyl, indolyl). Exemplary heteroaryl groups have from 5 to 14 ring atoms and contain from 1 to 5 ring heteroatoms independently selected from nitrogen (N), oxygen (O), or sulfur (S). One or more N or S atoms in a heteroaryl group can be oxidized. Heteroaryl groups can be unsubstituted or substituted. The term “N-containing heteroaryl” refers to heteroaryl groups which comprise at least one nitrogen in the ring system (e.g., a heteroaryl comprising 1, 2, or 3 nitrogen atoms). In embodiments, the foregoing groups, as derived from the groups listed above, are C-attached or N-attached where such is possible. Further, the term “hetero aryloxy” refers to the group -O-heteroaryl, where the group is attached to the parent molecular structure via the oxygen. Non-limiting examples of heteroaryl groupsAttorney Docket No.: 778138: CST9-008PC are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. Non-limiting examples of heteroaryl rings containing a single ring include: 1,2,3,4-tetrazolyl, [l,2,3]triazolyl, [l,2,4]triazolyl, triazinyl, thiazolyl, IH-imidazolyl, oxazolyl, furanyl, thiopheneyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3-methylpyridinyl, and 4-dimethylaminopyridinyl. Nonlimiting examples of heteroaryl rings containing 2 or more fused rings include: benzofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, cinnolinyl, naphthyridinyl, phenanthridinyl, 7H-purinyl, 9H-purinyl, 6-amino-9H-purinyl, 5H-pyrrolo[3,2-d]pyrimidinyl, 7H-pyrrolo[2,3-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, 2-phenylbenzo[d]thiazolyl, 1H-indolyl, 4,5,6,7-tetrahydro-1-H-indolyl, quinoxalinyl, 5-methylquinoxalinyl, quinazolinyl, quinolinyl, 8-hydroxy-quinolinyl, 1H-benzo[d]imidazol-2(3H)-onyl, lH-benzo[d]imidazolyl, and isoquinolinyl. One nonlimiting example of a heteroaryl group as described above is C1-C5 heteroaryl, which has 1 to 5 carbon ring atoms and at least one additional ring atom that is a heteroatom (preferably 1 to 4 additional ring atoms that are heteroatoms) independently selected from nitrogen (N), oxygen (O), or sulfur (S). Examples of C1-C5 heteroaryl include, but are not limited to, triazinyl, thiazol-2-yl, thiazol-4-yl, imidazol-l-yl, 1H-imidazol-2-yl, 1H-imidazol-4-yl, isoxazolin-5-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl.

[0447] Heteroarylene: The term “heteroarylene,” as used herein, represents a divalent form of a heteroaryl group as described herein.

[0448] Heteroarylalkyk The term “heteroarylalkyl” refers to an -(alkylene)-heteroaryl radical where heteroaryl and alkylene are as disclosed herein and which are optionally substituted by one or more of the exemplary substituent groups described herein. The “heteroarylalkyl” group is bonded to the parent molecular structure through the alkylene moiety. The term “heteroarylalkoxy” refers to an -O-[heteroarylalkyl] radical (-O-[(alkylene)-heteroaryl]), which is attached to the parent molecular structure through the oxygen.

[0449] Attorney Docket No.: 778138: CST9-008PC

[0450] Heterocycloalkyl: The term “heterocycloalkyl” or “heterocyclyl” as used herein, is a non-aromatic ring wherein at least one atom is a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus, preferably such as nitrogen, oxygen, or sulfur, and the remaining atoms are carbon, and with the proviso that the ring of said group does not contain two adjacent O or S atoms. In embodiments, a “heterocycloalkyl” or “heterocyclyl” refers to groups containing one to four heteroatoms each selected from O, S and N, wherein each heterocycle group has from 4 to 10 atoms in its ring system, and with the proviso that the ring of said group does not contain two adjacent O or S atoms. Herein, whenever the number of carbon atoms in a heterocycle is indicated (e.g., Ci-Ce-heterocycle), at least one other atom (the heteroatom) must be present in the ring. Designations such as “Ci-Ce-heterocycle” refer only to the number of carbon atoms in the ring and do not refer to the total number of atoms in the ring. In embodiments, it is understood that the heterocycle ring has additional heteroatoms in the ring. Designations such as “4-6-membered heterocycle” refer to the total number of atoms that are contained in the ring (i.e., a four, five, or six membered ring, in which at least one atom is a carbon atom, at least one atom is a heteroatom and the remaining two to four atoms are either carbon atoms or heteroatoms). In embodiments, in heterocycles that have two or more heteroatoms, those two or more heteroatoms are the same or different from one another. In embodiments, heterocycles are optionally substituted. In embodiments, binding to a heterocycle is at a heteroatom or via a carbon atom (i.e., in embodiments, the foregoing groups, as derived from the groups listed above, are C-attached or N-attached where such is possible). Examples of heterocycloalkyl groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl and quinolizinyl. In embodiments, heterocyclic moieties having a single ring include: diazirinyl, aziridinyl, urazolyl, azetidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolidinyl, isothiazolyl, isothiazolinyl oxathiazolidinonyl, oxazolidinonyl, hydantoinyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperazinyl,

[0451] Attorney Docket No.: 778138: CST9-008PC piperidinyl, dihydropyranyl, tetrahydropyranyl, piperidin-2-onyl (valerolactam), 2,3,4,5-tetrahydro-1H-azepinyl, 2,3-dihydro-1H-indole, and 1,2,3,4-tetrahydro-quinoline. Nonlimiting examples of heterocyclic moieties having 2 or more rings include: hexahydro-1H-pyrrolizinyl, 3a,4,5,6,7,7a-hexahydro-1H-benzo[d]imidazolyl, 3a,4,5,6,7,7a-hexahydro-1H-indolyl, 1,2,3,4-tetrahydroquinolinyl, chromanyl, isochromanyl, indolinyl, isoindolinyl, and decahydro-1H-cycloocta[b]pyrrolyl. The heterocycloalkyl group can be substituted or unsubstituted. The heterocycle groups include benzo-fused ring systems and ring systems substituted with one or two oxo (=0) moieties such as pyrrolidin-2-one. In embodiments, depending on the structure, a heterocycle group is a monoradical or a diradical (i.e., a heterocyclene group). The heterocycles described herein are substituted or unsubstituted. In embodiments, a heterocycle is substituted with 0, 1, 2, 3, or 4 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkylthioalkyl, alynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxyl, hydroxyalkylene, mercapto, nitro, amino, and amido moieties.

[0452] Substituted'. The term “substituted” is defined herein as a moiety, whether acyclic or cyclic, which has one or more hydrogen atoms replaced by a substituent or several (e.g., 1 to 10) substituents as defined herein below. The substituents are capable of replacing one or two hydrogen atoms of a single moiety at a time. In addition, these substituents can replace two hydrogen atoms on two adjacent carbons to form said substituent, new moiety or unit.

[0453] The variable groups defined herein, e.g., alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, aryloxy, aryl, heterocycle and heteroaryl groups defined herein, whether used alone or as part of another group, can be optionally substituted. Optionally substituted groups will be so indicated.

[0454] Moiety'. The term “moiety” refers to a specific segment or functional group of a molecule. Chemical moieties are often recognized chemical entities embedded in or appended to a molecule.

[0455] Nitro'. The term “nitro” refers to a -NO2 group.

[0456] Nitrogen protecting group'. In certain embodiments, the substituent present on a nitrogen atom is a nitrogen protecting group (also referred to as an amino protecting group or an N-protecting group). Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W.

[0457] Attorney Docket No.: 778138: CST9-008PC

[0458] Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999. For example, nitrogen protecting groups such as amide groups (e.g., - C(=O)Raa) include, but are not limited to, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3 -pyridylcarboxamide, N-benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide, o-nitophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N’-dithiobenzyloxyacylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine derivative, o-nitrobenzamide and o-(benzoyloxymethyl)benzamide.

[0459] Nitrogen protecting groups such as carbamate groups (e.g., -C(=O)ORaa) include, but are not limited to, methyl carbamate, ethyl carbamante, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9-(l 0, 10-dioxo- 10,10,10,10-tetrahydrothioxanthyl)] methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2 -phenylethyl carbamate (hZ), l-(l-adamantyl)-l -methyl ethyl carbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate, l,l-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC), l,l-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1 -methyl- 1 -(4-biphenylyl)ethyl carbamate (Bpoc), l-(3,5-di-t-butylphenyl)-l -methylethyl carbamate (t-Bumeoc), 2-(2’-and 4’-pyridyl)ethyl carbamate (Pyoc), 2-(N, N-dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1 -isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(l,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc),Attorney Docket No.: 778138: CST9-008PC l,l-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, t-amyl carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxyacylvinyl carbamate, o-(N, N-dimethylcarboxamido)benzyl carbamate, 1,1-dimethyl-3-(N, N-dimethylcarboxamido)propyl carbamate, 1, 1 -dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p’-methoxyphenylazo)benzyl carbamate, 1 -methylcyclobutyl carbamate, 1-methylcyclohexyl carbamate, 1-methyl-l-cyclopropylmethyl carbamate, 1 -methyl- 1(3,5 -dimethoxyphenyl)ethyl carbamate, 1 -methyl- l-(p-phenylazophenyl)ethyl carbamate, 1-methyl-l-phenylethyl carbamate, 1- methyl- l-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, and 2,4,6-trimethylbenzyl carbamate.

[0460] Nitrogen protecting groups such as sulfonamide groups (e.g., -S(=O)2Raa) include, but are not limited to, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6,-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4’,8’-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.

[0461] Other nitrogen protecting groups include, but are not limited to, phenothiazinyl-(10)-acyl derivative, N’-p-toluenesulfonylaminoacyl derivative, N’ -phenylaminothioacyl derivative, N-benzoylphenylalanyl derivative, N-acetylmethionine derivative, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N- 1,1, 4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5-substituted 1,3-dimethyl-

[0462] Attorney Docket No.: 778138: CST9-008PC l,3,5-triazacyclohexan-2-one, 5-substituted l,3-dibenzyl-l,3,5-triazacyclohexan-2-one,

[0463] 1- substituted 3,5-dinitro-4-pyridone, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(l-isopropyl-4-nitro-2-oxo-3-pyroolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N-2,7 -dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fem), N- 2- picolylamino N’-oxide, N- 1,1 -dimethylthiomethyleneamine, N-benzylideneamine, N-p-methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, N-(N’, N’-dimethylaminomethylene)amine, N, N’ -isopropylidenediamine, N-p-nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine, N-borane derivative, N-diphenylborinic acid derivative, N-[phenyl(pentaacylchromium- or tungsten)acyl] amine, N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, and 3-nitropyridinesulfenamide (Npys).

[0464] Whenever a term (e.g., alkyl or aryl) or either of their prefix roots e.g., alk-or ar-) appear in a name of a substituent the name is to be interpreted as including those limitations provided herein. For example, affixing the suffix “-ene” to a group indicates the group is a divalent moiety, e.g., arylene is the divalent moiety of aryl, heteroarylene is the divalent moiety of heteroaryl, cycloalkylene is the divalent moiety of cycloalkyl, heterocycloalkylene is the divalent moiety of heterocycloalkyl, or heterocyclelene is the divalent moiety of heterocyclyl. Similarly, affixing the suffix “-oxy” to a group indicates the group is attached to the parent molecular structure through an oxygen atom (-O-) (e.g., cycloalkyloxy, benzyloxy, and the like).

[0465] Attorney Docket No.: 778138: CST9-008PC

[0466] Synthetic Methods

[0467] Compounds described herein can be prepared according to methods known in the art. Accordingly, disclosed compounds can generally be synthesized by an appropriate combination of generally well-known synthetic methods and radiosynthesis systems. Techniques useful in synthesizing these chemical entities are both readily apparent and accessible to those of skill in the relevant art, based on the instant disclosure. Many of the optionally substituted starting compounds and other reactants are commercially available, e.g., from Aldrich Chemical Company (Milwaukee, Wis.) or can be readily prepared by those skilled in the art using commonly employed synthetic methodology.

[0468] For example, the exemplary synthetic methods described in the instant Examples can be used to prepare still other compounds used in the invention.

[0469] EXAMPLES

[0470] While certain compositions and methods of the present invention have been described with specificity in accordance with certain embodiments, the following example serves only to illustrate the compounds and methods of the invention, and it is not intended to limit the same.

[0471] Example 1. Comparison of small molecules and angiotensin-(l-7) in a diabetic mouse model

[0472] Naturally occurring peptide angiotensin-(l-7) is useful in the treatment of epidermolysis bullosa (EB) and was granted orphan designation by the European Commission in 2017 (EU / 3 / 17 / 1879).

[0473] The small compounds of the invention described herein show similar biological effects in disease models when compared to angiotensin-(l-7). For example, use of Compound (4) in a diabetic mouse model shows similar effects on blood glucose as compared to angiotensin-(l-7). See Fig. 1. In this model, the mice received five consecutive injections with streptozotocin (STZ) to destroy most of the pancreatic beta cells. Treatment with angiotensin-(l-7) or M13 began twenty- four hours after the last STZ injection. Thus, the small compounds of the invention can be to also be useful for treating blistering skin diseases like EB, in particular if their mechanism of action is similar.

[0474] Attorney Docket No.: 778138: CST9-008PC

[0475] Example 2. Receptor binding studies

[0476] Compounds described herein were studied using Receptor-transferred HEK293 cells using intracellular cAMP as a readout. Table 1 provides exemplary data from these studies, whereby 1 means 100% of the effect observed with 10-7M angiotensin-(l-7) and the numbers in brackets illustrate the most efficient concentrations.

[0477] Table 1

[0478]

[0479] Fig. 2 shows that Compound (3) has a similar effect to angiotensin-(l-7) in Mesangial cells.

[0480] Fig. 3 depicts similar receptor-binding studies of Compound (5).

[0481] This shows that the small compounds of the invention have a mechanism of action like angiotensin-(l-7).

[0482] Example 3. Ussing Chamber Studies

[0483] This example studies compounds of the invention in Ussing Chamber studies, which can be used to evaluate, for example, epithelial barrier protection.

[0484] Intestinal preparations were mounted in Ussing chambers (exposed area of 0.12 cm2) with 8 ml of Krebs solution (95% 02 / 5% CO2, 37°C) in the basolateral and luminal reservoirs. Tissues were voltage-clamped at 0 mV using an automatic voltage clamp (EVC 4000, World Precision Instruments, Sarasota, Florida), and the short-circuit current (Isc) required to maintain the potential at 0 mV was monitored as a reflection of the net active ion transport across the epithelium. To compromise the barrier function, 0.1 pg of PTX (Pertussis toxin) was used, and after 10 minutes, the compounds were added to the chambers in a 10-11 and 10-7 M concentration as 10 minutes intervals, and EA (Endogenous agonist) was used as a control. The resistance was calculated using Ohms law. The experiments were carried out simultaneously in chambers connected to a PC equipped with DataTrax II software (WPI). The transepithelial electrical resistances from the Ussing chamber studies are depicted in Fig. 4.

[0485] Attorney Docket No.: 778138: CST9-008PC

[0486] The data confirm that the small compound of the invention can act via Mas / MrgD in view of the lack of response from double knockout mice whereas a response is observed with the AT2 specific agonist EA.

[0487] Example 4. Angiotensin-(l-7), a Mas / MrgD receptor agonist, alleviates split formation in a human skin organ culture (HSOC) model of pemphigus and pemphigoid disease

[0488] A human skin organ culture (HSOC) model has been developed that reproduces the clinical phenotype of autoantibody-induced tissue pathology in pemphigus and pemphigoid disease. A recombinant single-chain variable fragment (scFv) targeting both desmoglein 1 (Dsg 1) and desmoglein 3 (Dsg3) is injected into pieces of human skin obtained surgically from abdomen or breast tissue, for example, to induce blistering. (Hartmann et al., Laboratory Animals, January 2023). The scFv injected alone is also referred to as a positive control herein for the model. As a negative control for the model, IVIG (intravenous immunoglobulins) were administered instead of the scFv. The human skin organ cultures were subsequently treated with different concentrations of angiotensin-(l-7), either supplemented in the medium or injected. Angiotensin-(l-7) was always administered in combination with the scFv. Samples were embedded in paraffin and cryomatrix, sectioned and immunostaining was performed on cryosections. Direct immunofluorescence was carried out for scFv. Immunostaining was quantified with ImageJ software on images obtained with identical microscope settings.

[0489] Split formation was measured and plotted in Fig. 5 A-5C. relative to concentration of angiotensin-(l-7), for example, from 0.01 pM to 1 pM or 100 pM. As a positive control, scFv to mimic autoantibodies was used. Fig. 5A shows percent split formation at various concentrations of angiotensin-(l-7) from 0.01 pM to 100 pM supplemented in HSOC medium in HSOC. The reduction in split formation was significant over control at all concentrations of angiotensin-(l-7) when added to medium (p<0.0001, IVIG / scFV, IVIG / 0.01 pM, IVIG / 0.1 pM, IVIG / 1 pM, IVIG / 100 pM by Kruskal- Wallis test). Fig.

[0490] 5B shows percent split formation at various concentrations of angiotensin-(l-7) from 0.01 pM to 100 pM injected in HSOC. The reduction in split formation was significant over control at all concentrations of angiotensin-(l-7) when injected (p<0.0001, IVIG / scFV, IVIG / 0.01 pM, IVIG / 0.1 pM, IVIG / 1 pM, IVIG / 100 pM by Kruskal- Wallis test). The

[0491] Attorney Docket No.: 778138: CST9-008PC reduction in split formation was significant over scFv at 0.1 pM concentration of angiotensin-(l-7) when injected (p < 0.05, scFv / 0.1 uM by Mann- Whitney test).

[0492] Table 2. Percent Split formation upon angiotensin-(l-7) administration in HSOC

[0493]

[0494] Fig. 5C shows percent split formation at various concentrations of angiotensin-(l-7) from 0.01 pM to 1 pM injected in HSOC The reduction in split formation was significant over control in injected samples (p<0.001, IVIG / scFV,

[0495] IVIG / 0.01 pM, IVIG / 0.1 pM, IVIG / 1 pM; p<0.01, scFV / 0.1 pM, scFV / 1 pM by Kruskal-Wallis test; p<0.05, scFV / 0.01 pM by Mann- Whitney test).

[0496] Table 3. Percent Split formation upon angiotensin-(l-7) injection in HSOC

[0497]

[0498] Fig. 6 shows histopathogic analysis of split formation in the human skin organ culture model. While an scFv positive control against desmoglein 1 and 3 autoantibodies, shows pronounced split formation in the microscopic images, an angiotensin-(l-7) injected sample shows decreased split formation, indicative of amelioration of an autoimmune blistering skin disease such as pemphigus and pemphigoid disease.

[0499] Attorney Docket No.: 778138: CST9-008PC

[0500] Overall, angiotensin-(l-7) treatment resulted in a significant reduction in split formation, indicative of treatment of an autoimmune blistering skin disease such as pemphigus and pemphigoid disease.

[0501] Example 5. Different Mas / MrgD receptor agonists (angiotensin-(l-7) and the small compound of the invention) reduce skin lesions in a preclinical model of Epidermolysis Bullosa Acquisita.

[0502] The passive Epidermolysis Bullosa Acquisita (EBA) mouse model provides a robust and reproducible platform for investigating the immunopathogenesis of this antibody-mediated blistering disease of the skin and evaluating novel treatment strategies. The passive EBA mouse model is induced by the tail vein injection of anti-type VII collagen IgG antibodies, generated in rabbits by immunization against type VII collagen, into C57BL / 6 mice at day 0 and day 2. The daily subcutaneous injected treatment of the randomized mice with PBS, angiotensin-(l-7) (lOOOpg / kg / day), or compound M13B (disodium salt; 200pg / kg / day or 0.2pg / kg / day) starts at day 3 and is continued until day 11. The scoring as well as the blood collection is executed at day 4, 8 and 12, whereby the scoring at day 12 is completed with the organ removal. The scoring involves the evaluation of the general health and the area of affected skin in percent.

[0503] Fig. 7A shows the scoring on day 12 for individual mice (males and females) as well as mean values of the treatment groups for angiotensin-(l-7) and the small compound of the invention. The reduction of affected skin area was highly significant (Ordinary one-way ANOVA, multiple comparisons). Fig. 7B shows the scoring in more detail for the small compound of the invention, i.e. on days 4, 8 and 12. The difference to control became more pronounced over time and was significant from day 8 on (Sidak’s multiple comparison test and Unpaired t-test).

[0504] This animal model confirms that the small compound of the invention can be used to treat blistering skin diseases like angiotensin-(l-7).

[0505] Example 6. Synthesis for Exemplary Compounds

[0506] Compounds (l)-(36) can be prepared according to methods known in the art. Exemplary methods and characterization data are provided below.

[0507] Compound (5) is synthesized according to the steps shown below.

[0508] Step 1.

[0509] Attorney Docket No.: 778138: CST9-008PC

[0510]

[0511] A suspension of A (1.09 g), B (1.41 g) and potassium carbonate (4.15 g) in dimethylacetamide (DMA) was stirred at 80 °C for 72h. After the reaction was deemed completion, water was added to the reaction mixture. C (2.3 g) was collected from precipitation.

[0512] Step 2.

[0513]

[0514] To a solution of C (230 mg) in acetonitrile was added D (154 mg) and the reaction mixture was stirred at room temperature for overnight. After the reaction was deemed completion, the reaction mixture was concentrated under reduced pressure and E (384 mg) was obtained.

[0515] Step 3.

[0516]

[0517] E Compound (5)

[0518] E (384 mg) was dissolved in MeOH. To the resulting solution, aqueous HCI was added, followed by a suspension of Pd / C (containing 40 mg Pd) in water. The resulting mixture underwent a gas exchange with argon by evacuation under reduced pressure and backfilling with argon. The gas exchange process was repeated for three times. The resulting mixture underwent an additional gas exchange with hydrogen (H2) by evacuation under reduced pressure and backfilling with hydrogen. The resulting suspension was stirred under H2 for overnight. The resulting mixture underwent a gas exchange with argon for three times and the suspension was filtered with a pad of celite.

[0519] Attorney Docket No.: 778138: CST9-008PC

[0520] The filtrate was concentrated under reduced pressure. The crude product was purified by prep-HPLC, followed by treatment with NaOH. The resulting material was further lyophilized to dryness, giving a mixture of Compound (5) (100 mg) and its corresponding sodium salt (94 mg).

[0521] The compounds (l)-(36) can also be synthesized through the below synthetic route.

[0522]

[0523]

[0524] Step-3

[0525]

[0526]

[0527] NaOH / H2O

[0528]

[0529] M13(2)20, cis racemic disodium salt

[0530] Attorney Docket No.: 778138: CST9-008PC

[0531] SM-1 is reduced to provide the SM-1A. The aniline derivative was acetylated to SM-2. Starting material 3 was O-arylated with SM-2 to access intermediate 4, which is reduced to provide intermediate 5. Intermediate 5 is further acetylated to intermediate 6, which is subjected to the Suzuki coupling to provide benzylated intermediate 8. An exhaustive deprotection of the acetamidyl groups of intermediate 8 delivers free amine intermediate 9, which is acetylated with compound 10 to M13(2)20. At this point, the disodium salt of M13(2)2 can be prepared by treating with sodium base and subsequent lyophilization to afford disodium salt of Ml 3(2)20.

[0532] Provided herein are characterization data for certain compounds of the synthetic route.

[0533] 4-amino-3 -bromophenol SM-1A (8 g, 92.76 % Yield, brown solid): 1H NMR (DMSO-d6) 8: 8.79 (s, 1H), 6.78 (d, J = 2.8 Hz, 1H), 6.66 (d, J = 8.6 Hz, 1H), 6.55 (dd, J = 8.8, 2.4 Hz, 1H), 4.60 (s, 2H) ppm. LCMS: (ES+) 94.76%, m / z = 189.70 [M+H],

[0534] N-(2-bromo-4-hydroxyphenyl) acetamide SM-2 (800 mg, 70 % Yield, brown solid): 1H NMR (DMSO-d6) 8: 9.78 (br s, 1H), 9.28 (s, 1H), 7.22 (d, J = 8.8 Hz, 1H), 7.00 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 8.8, 2.0 Hz, 1H), 2.00 (br s, 3H) ppm. LCMS: (ES+) 94.36%, m / z = 231.96 [M+H],

[0535] N-(2-bromo-4-(4-nitrophenoxy) phenyl) acetamide 4 (2.3 g, 75% Yield, paleyellow solid): 1H NMR (DMSO-d6) 8: 9.52 (br s, 1H), 8.27 (d, J = 9.2 Hz, 2H), 7.66 (d, J = 8.8 Hz, 1H), 7.54 (d, J = 2.4 Hz, 1H), 7.15-7.24 (m, 3H), 2.09 (s, 3H) ppm. LCMS: (ES+) 96.86%, m / z = 352.71 [M+H]

[0536] N-(4-(4-aminophenoxy)-2-bromophenyl) acetamide 5 (40 g, 87.4% Yield, pale pink solid): 1H NMR (DMSO-d6) 8: 9.40 (br s, 1H), 7.39 (d, J = 8.8 Hz, 1H), 7.04 (br s, 1H), 6.87 (d, J = 8.8 Hz, 1H), 6.75-6.83 (m, 2H), 6.60 (d, J = 8.8 Hz, 2H), 5.04 (s, 2H), 2.03 (s, 3H) ppm. LCMS: (ES+) 92.13%, m / z = 322.84 [M+H],

[0537] N-(4-(4-acetamido-3-bromophenoxy) phenyl) acetamide 6 (40 g, 88.4% Yield, brown gummy): 1H NMR (DMSO-d6) 8: 9.98 (s, 1H), 9.44 (br s, 1H), 7.58-7.64 (d, J = 8.8 Hz, 2H), 7.47 (d, J = 8.8 Hz, 1H), 7.19 (br s, 1H), 7.02 (d, J = 8.8 Hz, 2H), 6.95 (dd, J = 8.8, 2.4 Hz, 1H), 2.04 (br s, 6H) ppm. LCMS: (ES+) 93.14%, m / z = 364.94 [M+H],

[0538] N-(4-(4-acetamido-3-benzylphenoxy) phenyl) acetamide 8 (13 g, 90.08% Yield, off white solid): 1H NMR (DMSO-d6) 8: 7.53 (d, J = 8.8 Hz, 2H), 7.21-7.31 (m, 3H), 7.12-7.19 (m, 3H), 6.90 (d, J = 8.8 Hz, 2H), 6.69-6.75 (m, 2H), 3.91 (s, 2H), 2.01 (s, 3H), 1.94 (br s, 3H) ppm. LCMS: (ES+) 86.74%, m / z = 375.1 [M+H],

[0539] Attorney Docket No.: 778138: CST9-008PC

[0540] 4-(4-aminophenoxy)-2 -benzylaniline 9 (8 g, 52 % Yield, off white solid): 1H NMR (DMSO-d6) 8: 7.24-7.30 (m, 2H), 7.14-7.22 (m, 3H), 6.56-6.62 (m, 3H), 6.46-6.53 (m, 4H), 4.76 (s, 2H), 4.60 (s, 2H), 3.75 (s, 2H) ppm. LCMS: (ES+) 94.70%, m / z = 291.67 [M+H],

[0541] cis-2-((4-(3-benzyl-4-(cis-2-carboxy cyclohexane- 1 -carboxamido) phenoxy) phenyl)carbamoyl)cyclohexane-l -carboxylic acid Ml 3(2)20 (14 g, 71.0% Yield, off white solid): 1H NMR (DMSO-d6) 8: 11.95 (br s, 2H), 9.70 (br s, 1H), 9.15 (br s, 1H), 7.54 (d, J = 8.0 Hz, 2H), 7.25 (d, J = 6.8 Hz, 2H), 7.12-7.21 (m, 4H), 6.88 (d, J = 8.0 Hz, 2H), 6.69-6.77 (m, 2H), 3.82-3.98 (m, 2H), 2.92 (br s, 2H), 1.93-2.10 (m, 4H), 1.57-1.74 (m, 6H), 1.24-1.46 (m, 8H) ppm. LCMS: (ES+) 92.27%, m / z = 599.4 [M+H], HPLC: 89.41 % Purity [method: Column: X-Select CSH Cl 8 (4.6*150) mm 5u, Mobile Phase: A - 0.1% Formic acid in water: Acetonitrile (95:05), B - Acetonitrile].

[0542] Sodium cis-2-((4-(3 -benzyl-4-(cis-2-carboxylatocyclohexane- 1 -carboxamido)phenoxy)phenyl) carbamoyl)cyclohexane-l -carboxylate Ml 3(2)20 cis racemic disodium salt (18 g, 44.2% Yield, off white solid): 1H NMR (DEUTERIUM OXIDE) 8: 7.42 (d, J = 9.0 Hz, 2H), 7.33-7.39 (m, 2H), 7.25-7.31 (m, 2H), 7.21 (d, J = 6.8 Hz, 2H), 7.12 (d, J = 9.2 Hz, 2H), 7.04-7.06 (m, 1H), 7.03 (s, 1H), 3.97 (s, 2H), 2.86- 2.92 (m, 1H), 2.73-2.79 (m, 2H), 2.66 (dt, J = 7.6, 4.0 Hz, 1H), 1.99-2.13 (m, 3H), 1.73- 1.93 (m, 3H), 1.54-1.72 (m, 5H), 1.47 (dd, J = 11.6, 6.0 Hz, 5H) ppm. LCMS: (ES+) 96.29%, m / z = 599.4 [M+ 2Na], HPLC: 96.06 % purity [Column: X-Bridge Cl 8 (4.6*150) mm 5u, Mobile Phase: A - 5mM Ammonium Bicarbonate in water, B -Acetonitrile].

[0543] The relative stereochemistry of Ml 3(2)20 was assigned by nuclear Overhauser effect experiment via the 1H NMR spectroscopy.

Claims

Attorney Docket No.: 778138: CST9-008PCCLAIMSA compound for use in treating a blistering skin disease, wherein the compound is an agonist of Mas receptor and / or MrgD receptor and wherein the compound has a structure according to(a) Formula (A)or a pharmaceutically acceptable salt thereof, whereineach of R1and R5is independently H or Ci-Ce alkyl;R2is independently H, OH, or (CH2)PCO2R5;R3is independently Ci-Ce alkyl, 1- to 6-membered heteroalkyl, or X1-R6;R4is independently Ci-Ce alkyl, 1- to 6-membered heteroalkyl, or X1-R6, or two R4on adjacent carbons combine to form a heteroaryl moiety, or one R4combines with R7Bto form a heteroaryl moiety;L1is independently a covalent bond, C(O), C(O)NR7A, or NR7AC(O);L2is independently a covalent bond, CH2, C(O), NR7B, C(O)NR7B, or NR7BC(O);R6is independently Ce-Cio aryl or 5- to 10-membered heteroaryl;each R7Ais independently H or Ci-Ce alkyl;each R7Bis independently H or Ci-Ce alkyl, or R7Bcombines with R4to form a heteroaryl moiety;X1is independently a covalent bond, O, or CH2;Cy is independently C5-C10 cycloalkyl, 5- to 7-membered heterocyclyl, 5- to 6-membered heteroaryl or phenyl;each of m, n, and o is independently 0, 1, or 2;p is independently 0 or 1; andq is independently 0, 1, 2, or 3; or(b) Formula (B),Attorney Docket No.: 778138: CST9-008PCor is a pharmaceutically acceptable salt thereof, whereinR2is independently H, OH, or (CH2)PCO2R5;R4is independently Ci-Ce alkyl, 1- to 6-membered heteroalkyl, or X’-R6, or two R4on adjacent carbons combine to form a heteroaryl moiety, or one R4combines with R7Bto form a heteroaryl moiety;X1is independently a covalent bond, O, or CH2;R5is independently H or Ci-Ce alkyl;R6is independently Ce-Cio aryl or 5- to 10-membered heteroaryl;each R7Bis independently H or Ci-Ce alkyl, or R7Bcombines with R4to form a heteroaryl moiety;L2is independently a covalent bond, C(O), NR7B, C(O)NR7B, or NR7BC(O);Cy is independently C5-C7 cycloalkyl, 5- to 7-membered heterocyclyl, 5- to 6-membered heteroaryl or phenyl;each of n and 0 is independently 0, 1, or 2; andp is independently 0, 1, 2, or 3.

2. The compound for use of claim 1, wherein the blistering skin disease is an immunobullous or a nonimmunobullous blistering skin disease.

3. The compound for use of claim 2, wherein the immunobullous blistering skin disease is pemphigus, preferably selected from the group consisting of pemphigus vulgaris, pemphigus foliaceus, IgA pemphigus, paraneoplastic pemphigus, pemphigus vegetans, drug-induced pemphigus, pemphigus erythematosus (Senear-Usher syndrome), endemic pemphigus (fogo selvagem), benign familial pemphigus (Hailey-Hailey disease), and combinations thereof.

4. The compound for use of claim 2, wherein the immunobullous blistering skin disease is pemphigoid, preferably selected from the group consisting of bullous pemphigoidAttorney Docket No.: 778138: CST9-008PC(BP), mucous membrane pemphigoid (MMP, or cicatricial pemphigoid), pemphigoid gestationis, epidermolysis bullosa acquisita, linear IgA disease, anti-laminin gl / anti-p200 pemphigoid, lichen planus pemphigoides, pemphigoid disease characterised by renal insufficiency, and combinations thereof.

5. The compound for use of claim 2, wherein the nonimmunobullous blistering skin disease is associated with infection, is associated with a physical trauma, is associated with a drug, is associated with dermatitis, is a metabolic disorder or is a genetic disorder.

6. The compound for use of claim 5, wherein- the infection is a viral, bacterial or a fungal infection,- the physical trauma is a mechanical, thermal or cold trauma,- nonimmunobullous blistering skin disease associated with a drug is a fixed drug eruption (FDE) or Toxic epidermal necrolysis (TEN),- the dermatitis is contact dermatitis or phytophotodermatitis,- the metabolic disorder is porphyria, and / or- the genetic disorder is epidermolysis bullosa or incontinentia pigmenti.

7. The compound for use of any one of claims 1 to 6, wherein the compound is administered at an effective dose, preferably periodically at an administration interval, such that at least one symptom or feature of the blistering skin disease is reduced in intensity, severity, duration, or frequency or has delayed onset.

8. The compound for use of claim 7, wherein the one or more symptoms of the autoimmune blistering skin disease is selected from ulcers, blisters, eczema, hives, and combinations thereof, wherein the ulcers or blisters are preferably on skin or mucous membrane, and wherein the mucous membrane is preferably of mouth, nose, throat, eyes, or genitals.

9. The compound for use of any one of claims 1 to 8, wherein the administration is oral.Attorney Docket No.: 778138: CST9-008PC10. The compound for use of any one of claims 1 to 8, wherein the compound is administered in combination with one or more active ingredients / medication(s), preferably a sartane and / or one or more active ingredients / medication(s) that control the immune response, prevent secondary infections, promote wound healing and / or minimize pain and scarring.

11. The compound for use of any one of claims 1 to 10, wherein the compound has a structure according to Formula (I):or a pharmaceutically acceptable salt thereof, whereineach of L1, L2, R1, R2, R3, R4, Cy, m, n, and 0 is as defined in claim 1.

12. The compound for use of any one of claims 1 to 11, wherein the compound has a structure according to Formula (I-B):or a pharmaceutically acceptable salt thereof, whereinR4is independently Ci-Ce alkyl, 1- to 6-membered heteroalkyl, or X1-R6;R6is independently Ce-Cio aryl or 5- to 10-membered heteroaryl; andX1is independently a covalent bond, O, or CH2, preferablyR4is independently Ci-Ce alkyl, or X1-R6, most preferred R4is X1-R6;R6is independently Ce-Cio aryl, most preferred phenyl; andX1is independently a covalent bond, or CH2, CH2 being most preferred.Attorney Docket No.: 778138: CST9-008PC13. The compound for use of any one of claims 1 to 12, wherein the compound has a structure according to Formula (I-B”):or a pharmaceutically acceptable salt thereof, whereinR4is as defined in claim 12.

14. The compound for use of any one of claims 1 to 11, wherein the compound is selected from the group consisting ofAttorney Docket No.: 778138: CST9-008PCAttorney Docket No.: 778138: CST9-008PCAttorney Docket No.: 778138: CST9-008PCAttorney Docket No.: 778138: CST9-008PCAttorney Docket No.: 778138: CST9-008PCAttorney Docket No.: 778138: CST9-008PCor a pharmaceutically acceptable salt thereof.

15. The compound for use of any one of claims 1 to 12, wherein the compound is selected from the group consisting of:Attorney Docket No.: 778138: CST9-008PCor a pharmaceutical acceptable salt thereof.